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Summary in Norwegian 
 
Depresjon og symptomer på depresjon – kartlegging, klassifisering og behandling 
Depresjon og depressive symptomer er en belastning for pasienter med langtkommen kreft. 
Anslag som er gjort av forekomsten av depresjon hos pasienter med langtkommen kreft, 
varierer veldig; fra 3 til 58 %. Depresjon er dessuten ofte underdiagnostisert og 
underbehandlet til tross for at det finnes diagnostiske systemer og kliniske retningslinjer for 
depresjon.  
Hovedmålet med denne avhandlingen er å bidra til å forbedre kartlegging, klassifisering og 
behandling av depresjon og depressive symptomer hos pasienter med langtkommen kreft. 
Tre forskjellige studier ble gjennomført: en systematisk litteraturgjennomgang, en 
tverrsnittstudie av et stort antall europeiske kreftpasienter og en retrospektiv studie basert 
på legers observasjon av kreftpasienter i deres siste levedøgn. 
Variasjonen i anslagene av forekomsten av depresjon hos pasienter med langtkommen kreft, 
kan være relatert til kartleggingsmetoder, men også til heterogeniteten til 
studiepopulasjonen med hensyn til for eksempel alder, diagnose, spredning av 
kreftsykdommen og overlevelse. Presis beskrivelse av pasientpopulasjonener nødvendig for 
å kunne sammenligne resultater på tvers av studier og overføre forskningsfunn til klinisk 
praksis. Hovedproblemstillingen i den systematiske litteraturgjennomgangen var: Hvordan 
blir populasjoner av pasienter med langtkommen kreft karakterisert i studier om depresjon 
og symptomer på depresjon? Den systematiske litteraturgjennomgangen viste at de hyppigst 
rapporterte variablene i de inkluderte studiene var alder (93 %), kjønn (90 %) og 
kreftstadium (95 %). Depresjonsrelaterte variabler, som bruk av antidepressiva, ble 
rapportert i 17 % av studiene, mens tidligere depresjonsepisoder ble rapportert i 12 %. 
En annen mulig årsak til variasjonen i anslagene av forekomst kan være mangel på en 
standard for å definere og kartlegge depresjon hos pasienter med langtkommen kreft. 
Derfor er tydelige beskrivelser av metoder for kartlegging og klassifisering nødvendig for å 
bedømme hvorvidt studiefunnene er relevante for klinisk praksis. Den andre 
problemstillingen for den systematiske litteraturstudien var: Hvordan blir depresjon kartlagt 
og klassifisert i kliniske studier av pasienter med langtkommen kreft? Litteraturstudien 
konkluderte med at 25 % av studiene brukte validerte diagnostiske systemer for å 
klassifisere depresjon, for eksempel DSM og ICD klassifiseringssystem som bruker 
strukturerte og semistrukturerte intervju. 75 % av studiene brukte ikke et validert 
diagnostiseringssystem. De brukte imidlertid selv-rapporteringsverktøy som Hospital Anxiety 
and Depression Scale og forskjellige versjoner av the Beck Depression Inventory. 
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Det er altså stor variasjon i hvordan populasjonog kartleggingsmetoder blir beskrevet i 
studier av pasienter med langtkommen kreft og depresjon. En mer standardisert praksis er 
nødvendig for å forbedre generaliserbarheten og øke nytten av forskningsfunn. Sentrale 
aktører i fagfeltet bør oppmuntres til å utvikle anbefalinger for hvordan å beskrive 
pasientpopulasjon og hvilke kartleggingsmetoder som bør brukes i framtidige studier.  
Farmakologiske intervensjoner, som antidepressiva, behandler depressive lidelser hos 
kreftpasienter effektivt. Likevel blir langt fra alle kreftpasienter som har fått en 
depresjonsdiagnose, behandlet med antidepressiva. Hovedproblemstillingen i den andre 
studien, en internasjonal tverrsnittstudie (n=1048), var: Hva er forekomsten av bruken av 
antidepressiva blant pasienter med langtkommen kreft inkludert i en internasjonal 
multisenterstudie? Denne tverrsnittstudien rapporterte at forekomsten av bruken av 
antidepressiva var 14 % i et internasjonalt bekvemmelighetsutvalg av kreftpasienter med 
langtkommen kreft. 
Vi har manglet informasjon om hva som karakteriserer pasienter med langtkommen kreft 
som får behandling med antidepressiva. Derfor var den andre problemstillingen i 
tverrsnittstudien: Hvilke sosialdemografiske og medisinske variabler er assosiert med bruken 
av antidepressiva i pasienter med langtkommen kreft i en internasjonal multisenterstudie? I 
denne store internasjonale tverrsnittstudien ble følgende assosiert med bruk av 
antidepressiva mot depresjon hos pasienter med langtkommen kreft: ung alder, å være 
kvinne, bruk av smertestillende og tre eller flere komorbiditeter. Sykdomsrelaterte variabler 
som diagnose, stadium, allmenntilstand og overlevelsestid, var ikke assosiert med bruk av 
antidepressiva. Det mangler imidlertid fortsatt pålitelig informasjon om hvilke variabler som 
har innvirkning på legenes praksis med å foreskrive antidepressiva. 
Kreftpasienter som nærmer seg livets slutt, kan oppleve depresjon eller depressive 
symptomer. Det er imidlertid vanskelig å bedømme om pasientene opplever en normal 
dødsprosess, eller om det er en depresjon. Forskningsspørsmålet i den tredje studien, en 
retrospektiv dødsatteststudie (n=1363), var: Hva er forekomsten av depressive symptomer 
hos nederlandske pasienter med kreft det siste døgnet av livet i følge behandlende leges 
vurdering? Resultatene viste at forekomsten av depressive symptomer hos pasienter med 
kreft de siste 24 timene av livet var 37,6 %. Blant disse ble mild/moderat grad av depresjon 
registrert i 31,8 % og alvorlig/veldig alvorlig i 5,8 %. For å undersøke nærmere hva som 
kjennetegner kreftpasienter med depressive symptomer, ble følgende problemstilling 
adressert i samme studie: Er det en sammenheng mellom symptomer på depresjon og 
forskjellige sosialdemografiske variabler, kjennetegn ved pleie og symptomer i nederlandske 
kreftpasienter de siste 24 timene av levetiden? Det var en signifikant sammenheng mellom 
utmattelse og forvirring og milde/moderate symptomer på depresjon, mens angst var 
assosiert med både milde/moderate og alvorlige/veldig alvorlige symptomer på depresjon. 
Det at en spesialist i smerte eller palliasjon og psykiater/psykolog var involvet i behandlingen 
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var assosiert med at legene hyppigere vurderte at pasientene hadde alvorlige/veldig 
alvorlige symptomer på depresjon.  
Det er fortsatt behov for økt oppmerksomhet mot subjektive symptomer, inkludert 
depressive symptomer, hos pasienter med langtkommen kreft. Denne avhandlingen viser at 
det er nødvendig å øke helsepersonells kunnskap om kartlegging, klassifisering og 
behandling av depresjon og depressive symptomer hos pasienter med langtkommen kreft. 
Dette vil bidra til å optimalisere behandling og pleie til pasienter med kreft gjennom hele 
sykdomsforløpet. 
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Summary in English 
 
Depression and depressive symptoms are burdensome in patients with advanced cancer. 
Prevalence rate estimates of depression in patients with advanced cancer vary greatly; from 
3% to 58%.Furthermore, depression is often under diagnosed and under treated despite 
existing diagnostic systems and clinical guidelines for depression.  
The overall aim of this thesis is to contribute to improve assessment, classification and 
treatment of depression and depressive symptoms in patients with advanced cancer. 
Therefore, the steps described below were undertaken by three different studies; one 
systematic literature review, one cross-sectional study of a large sample of European 
patients with advanced cancer and one retrospective study based upon physicians’ 
observations of cancer patients at end of life. 
The variation in prevalence rates of depression in advanced cancer patients may be related 
to assessment methods, but also to the heterogeneity of the population studied with regard 
to for example age, diagnosis, extent of cancer disease, and survival. A precise 
characterisation of the study sample is needed to be able to compare results across studies 
and transfer research findings to clinical practice. The main research question in the 
systematic literature review was: How are populations of advanced cancer patients 
characterised in studies of depression and depressive symptoms? The systematic literature 
review revealed that the most frequently reported variables in the included studies were age 
(93%), gender (90%), and stage of cancer disease (95%). Depression-related variables such as 
use of antidepressants were reported in 17% of the studies and previous depressive 
episodes in 12%.  
Another possible reason for different prevalence rate estimates could be lack of agreed 
upon standards for defining and assessing depression in patients with advanced cancer. 
Therefore clear descriptions of the assessment and classification methods are necessary to 
judge the relevance of the study findings for clinical practice. A second research question in 
the systematic review was: How is depression assessed and classified in clinical studies in 
patients with advanced cancer? The systematic literature review concluded that 25% of the 
studies used validated diagnostic systems for classifying depression such as DSM and ICD 
classification system using structured and semi-structured interviews. 75% of the studies did 
not use a validated diagnostic system; however they used self-reported tools such as the 
Hospital Anxiety and Depression Scale and different versions of the Beck Depression 
Inventory. 
In summary, the current practice for describing sample characteristics and assessment 
methods for depression varies considerably between studies among patients with advanced 
cancer. More standardised practice is needed in order to enhance the generalizability and 
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utility of research findings. Stakeholders should be encouraged to produce 
recommendations for sample descriptions and assessment methods in future studies. 
Pharmacologic interventions including antidepressant medication are effective in treating 
depressive disorders in cancer patients. However, far from all cancer patients with a 
diagnosis of depression receive treatment with antidepressants. The main research question 
in the second study, an international cross-sectional study (n=1048) was: What is the 
prevalence of use of antidepressants usage among advanced cancer patients included in an 
international multicentre study? This cross-sectional study reported that the prevalence of 
antidepressants use was 14% in an international convenience sample of advanced cancer 
patients. 
Information on characteristics of patients with advanced cancer that are treated with 
antidepressants was still lacking. Therefore, a second research question in the cross-
sectional study was the following: Which socio-demographic and medical variables are 
associated with the use of antidepressants in advanced cancer patients included in an 
international multicentre study? In this large international cross-sectional study, younger 
age, female gender, current medication for pain, and presence of three or more 
comorbidities were associated with antidepressant use other than as adjuvant for pain in 
advanced cancer patients. Disease-related variables such as diagnoses, stage, performance 
status, and survival length were not associated with the use of antidepressants. However, 
precise information on which variables that are guiding physicians in prescribing 
antidepressant medication is still lacking. 
Cancer patients at the end of life may experience depression or depressive symptoms. 
However, it is difficult to judge whether the patients experience a normal dying process or 
depression. The research question in the third study, a retrospective death certificate study 
(n=1363) was: What is the prevalence of depressive symptoms in Dutch cancer patients in the 
last 24 hours of their life according to treating physicians’ ratings? Results showed that the 
prevalence of depressive symptoms in cancer patients in the last 24 hours of life reported by 
physicians was 37.6%. Among them mild/moderate depression was registered in 31.8% and 
severe/very severe in 5.8%.To further investigate what is characterizing cancer patients with 
depressive symptoms, the following research question was addressed in the same study: Is 
there an association between depressive symptoms and different socio-demographic 
variables, characteristics of care and symptoms in Dutch cancer patients their last 24 hours 
of life? Fatigue and confusion were significantly associated with mild/moderate depressive 
symptoms, while anxiety with both mild/moderate and severe/very severe depressive 
symptoms. Involvement of pain specialists or palliative care consultants and psychiatrists or 
psychologists was associated with more frequent-ratings of severe or very severe depressive 
symptoms.  
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Different symptoms and depressive symptoms in particular still call for special attention in 
patients with advanced cancer. Based on the results in this thesis there is a need for 
improved knowledge among health care providers about assessment, classification and 
treatment of depression and depressive symptoms in patients with advanced cancer. This 
will help optimizing care to patients with cancer throughout the disease trajectory. 
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1. BACKGROUND 
1.1 Preface 
Depression and depressive symptoms are burdensome in advanced cancer patients (1). 
Depression has been found to be an independent predictor of mortality (2) and is associated 
with increased disability and poor quality of life (3). The reported prevalence rates of 
depression vary greatly from 3% to 58% (4, 5). This may be due to e.g. different assessment 
methods and study designs and heterogeneity of the populations studied. In some studies 
different factors such as younger age (6), female gender (7) and certain cancer diagnosis (8-
10) have been associated with depression. Pharmacologic interventions including 
antidepressant medication are effective in treating depressive disorders in cancer patients 
(11). However, far from all cancer patients with a diagnosis of depression receive treatment 
with antidepressants (12-15). Furthermore, advanced cancer patients with depression may 
experience more pain and higher intensity of other symptoms then patients without those 
conditions (16, 17). 
 
Motivated by the lack of optimal symptom management in advanced cancer patients, the 
European Palliative Care Research Centre (PRC) (18) was established in 2009. The PRC aims 
at improving palliative care through research, education, and implementation of research 
findings in an international setting. The PRC is one of six partners in the “European 
Intersectorial and Multidisciplinary Palliative Care Research Training” (EURO IMPACT) project 
(19). EURO IMPACT is a four-year project funded by the European Union Seventh Framework 
Programme under Marie Skųodowska-Curie actions. EURO IMPACT is aiming to develop a 
multi-disciplinary, multi-professional and intersectorial educational and research training 
framework for palliative care researchers in Europe (2010-2014). As part of the EURO 
IMPACT project the candidate was responsible for conducting research in Norway and in the 
Netherlands. The present thesis has been conducted as a collaborative effort of the PRC and 
the EURO IMPACT project. 
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1.2 Oncology and palliative care 
1.2.1 Cancer 
Cancer is one of the leading causes of death in Europe. In 2012, the mortality rate and 
incidence rate of cancer were 1.75 million and 3.45 million in European countries, 
respectively (20). In the same year in Norway, 10 906 persons died from cancer and 30 099 
new patients received a cancer diagnosis (21). In the Netherlands 43 377 persons died and 
101 210 new patients were diagnosed in 2012 (22). 
 
1.2.2 Palliative care 
Patients with advanced cancer frequently experience many distressing symptoms (23-26) 
and one of the most important and essential goals of palliative care is optimal symptom 
control to achieve better quality of life (QOL). Palliative care is focusing on relieving, rather 
than curing, symptoms caused by cancer and other chronic life-threatening disease. It 
includes prevention, assessment and treatment of pain, physical, emotional and spiritual 
needs of the patients. The latest definition of palliative care from the World Health 
Organization (WHO), states that: “Palliative care is an approach that improves the quality of 
life of patients and their families, facing the problems associated with life threatening illness, 
through the prevention and relief of suffering by means of early identification and 
impeccable assessment and treatment of pain and other problems, physical, psychosocial 
and spiritual” (27). Depending on a need for a holistic multi-professional approach, 
systematic assessment, and symptom control, palliative care should according to this 
definition be provided for patients not only with advanced disease and at the end of life, but 
also for cancer patients receiving curative treatment, being cured or for patients with other 
chronic diseases than cancer (28). 
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Figure 1. Palliative care 
 
Reprinted with permission form Ferris et al. (29). 
 
In the UK, palliative medicine has been established as a medical specialty while e.g. in 
Norway it is a sub-specialty, and in the Netherlands no specialisation exists in palliative 
medicine at the time being (30). In the UK registered nurses usually have to complete an 
additional certification course in palliative care, while in Norway nurses can undertake a 
master degree in palliative care. In the Netherlands no specialisation in palliative care exists 
for nurses (30). 
 
The terminology used to describe the field palliative care is heterogeneous (31). Balfour 
Mount was the first who introduced the concept ‘palliative care’ in 1974 (32) and since then 
numerous other definitions have been proposed (31, 33). Examples of other terms in use are 
‘palliative medicine’, ‘supportive care’, ‘terminal care’, ‘hospice care’, ‘comfort care’, and 
‘end-of-life care’, covering different aspects and phases of a field focusing on patients’ and 
families’ QOL. End-of-life care is an important part of palliative care. However, there is no 
exact definition of what constitutes the time interval referred to as end of life. According to 
the European Association of Palliative Care White paper on standards and norms for hospice 
and palliative care (34), end of life can be understood as an extended period of one to two 
years during which the patient/family and health professionals become aware of the life-
limiting nature of the illness, while in clinical work end of life is usually understood more 
specifically as comprehensive care for dying patients in the last few hours or days of life (34). 
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End-of-life care aims at maintaining the functional capacity and good QOL as long as 
possible. To achieve this, good symptom management is needed. A systematic literature 
review identified 37 different symptoms reported in cancer patients, while 22 symptoms 
were identified as being the most common during the last one to two weeks of life, including 
fatigue, weight loss, weakness, and appetite loss as the most common (35). Place of death 
for patients with advanced cancer vary greatly across Europe (36). According to a recent 
systematic literature review on the preferences of death among cancer patients receiving 
palliative care, the majority of patients preferred to die at home (37). In the Netherlands 
home death occurs in 45% of cancer patients, while in Norway this percent lies around 13 
(36). 
 
1.2.3 Palliative care population 
The palliative care population is heterogeneous in terms of different patient characteristics 
such as age, diagnosis, extent of disease, survival, symptom burden, number of co-
morbidities, and physical functioning (38, 39). The palliative care patients studied in this 
thesis have advanced cancer, however, the palliative care population also include patients 
with other chronic life-threatening disease such as heart failure and neurological diseases 
(38). A recent systematic literature review by Moens et al. showed that palliative care 
patients within nine studied diagnostic groups had similar prevalence rates of different 
symptoms (40). Cancer patients in need of palliative care usually have multiple symptoms 
which fluctuate in intensity (23-26, 41). A major barrier identified in palliative care research 
is the lack of common criteria to define and describe the palliative care patient population 
(42). This limits the possibility to generalize findings from clinical studies (43-45). One 
European survey, where palliative care experts participated, showed that the patient 
populations were poorly described in studies and identified this as a major barrier for 
conducting high-quality research (46). Different initiatives have been proposed and 
advocated for standardized descriptions of patient samples in clinical studies in general (47, 
48) as well as in clinical studies in palliative care (45, 49-51). For example, Currow et al. have 
proposed a checklist to describe a palliative care populations as well as service 
characteristics in clinical studies (50). This checklist can also be used in advanced cancer 
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patients as the terms ‘palliative care’ and ‘advanced cancer populations’ overlap. The 
checklist includes five domains that should be assessed and reported including “individual 
participant’s demographics”, “caregiver”, “service”, “health and social policy” and “research” 
(50). 
 
Despite these initiatives, a recent systematic literature review by Sigurdardottir et al. 
demonstrated that the descriptions of palliative care cancer populations lack consistency 
even in randomized clinical trials (52). Thus, a consensus process was initiated by PRC (18) in 
collaboration with the Research Network of the European Association for Palliative Care 
(EAPC-RN) (53) and the EU-funded project PRISMA (“Reflecting the Positive diveRsities of 
European priorities for research and Measurement in end-of-life cAre”) (54) to develop a set 
of core variables to be registered when reporting clinical studies in palliative care. Using the 
Delphi approach, international experts in palliative care from 27 European countries and 
Australia, Canada, USA participated in the survey. The list of variables included socio-
demographics (e.g. age, gender, and education), intensity of 12 frequent cancer symptoms, 
supplemented by medical variables (e.g. diagnosis, treatment, co-morbidities, performance 
status) (55). Thirty-one variables were recommended as the mandatory set of variables 
when reporting results from palliative care cancer clinical trials (appendix). This set might 
need additional variables for studies that address specific conditions, e.g. depression and 
cachexia. 
 
The terms commonly used to describe a palliative care population are: ‘palliative cancer care 
patients’ ‘patients with advanced cancer’, ‘patients with incurable cancer’, ‘end-of-life 
cancer patients’. In this thesis the term ‘patients with advanced cancer’ / ‘advanced cancer 
patients’ will be used throughout the text. 
 
1.2.4 Patient reported outcomes 
Symptom assessment can be performed subjectively which represents reports received 
directly from the patients. ‘Patient reported outcomes’ (PROs) is an umbrella term including 
all signs, symptoms and information about physical and mental health as well as all aspects 
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on functioning, based on patients’ self-report (56, 57). The method of assessment of the 
PROs could be through direct interview of the patient, by pen and paper method or via 
electronic devices such as hand-held computers, web-based systems, or using mobile 
phones (58). Questionnaires are the most commonly used method for patients’ self-
reporting. Patient’s subjective experiences should be assessed routinely as it is an important 
prerequisite for optimal symptom relief (59). Prevalence rates of different symptoms may 
vary greatly depending for example on the type of questions, answer categories, time frame, 
and place where the questionnaire was filled in. PROs often play an important role in 
oncology clinical trials helping to evaluate the effect of cancer treatment and palliative care. 
Some major initiatives exist which promote, facilitate and improve PROs in general health 
care (60, 61). One of them is Patient-Reported Outcome Measurement Information System 
(PROMIS) which is a system of accurate measures of patient-reported health status for 
physical, mental, and social well-being. The use of PROs in clinical practice by patients with 
advanced cancer may be difficult as many of the patients experience multiple concurrent 
symptoms including cognitive impairment (e.g. confusion, and communication difficulties), 
as well as physical disabilities (e.g. severe weakness). Proxy reports from health care 
providers, family members, and/or caregivers in those conditions may facilitate symptom 
assessment. However, several studies have been conducted showing that health care 
providers often under-estimate different symptom severity or frequency in cancer patents 
(62-66). A study conducted in cancer outpatients showed that oncologists often 
underestimated psychological symptoms in patients (67). Family members and caregivers 
may also be a fair substitute for patient response as demonstrated in the study conducted in 
a hospice/palliative care setting (68). Authors suggest that symptoms and QOL reports 
should be obtained from all available respondents including family members throughout the 
course of clinical care or research in those settings. The benefits of the proxy reporting may 
compensate the limitations when studying patient groups with severe conditions. 
 
1.2.5 Quality of life and health related quality of life 
QOL is a broad multidimensional construct which does not have one precise common 
definition, however it includes components of happiness and an overall satisfaction with life 
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(69). In health care, the term Health Related Quality of Life (HRQOL) was introduced to 
distinguish between QOL in its more general sense and specific dimensions with particular 
relevance to health; e.g. somatic and psychological symptoms, level of functioning and 
emotional/spiritual well-being (Table 1). It helps to eliminate ambiguity and measure how 
the individual's well-being may be affected over time by a disease, disability, or disorder, and 
is therefore relevant in clinical practice and research trials. To assess and measure HRQOL, 
several tools have been developed during the past 20 years. These may be divided into three 
major groups: generic, disease-specific and domain-specific questionnaires (70). The generic 
questionnaires are intended for general use irrespective of the disease or the population 
studied. Therefore it can be administered to patients with different illnesses and even 
healthy subjects allowing making comparisons across different populations and conditions 
(e.g. Medical Outcome Study 36-Item Short Form (71), EuroQol (72)). The disease-specific 
questionnaires assess specific aspects of QOL and mostly address a particular disease or 
specific interventions related to certain diseases. They are mostly used to assess sub-
populations such as patients with cancer, arthritis, or diabetes including various aspects of 
functioning, such as physical, role and social functioning and subjective appraisal of 
symptoms and wellbeing. A widely used questionnaire which was developed to assess 
HRQOL in cancer patients is the European Organisation for Research and Treatment of 
Cancer Core Quality of Life Questionnaire; QLQ-C30 (73). The domain-specific questionnaires 
are used to assess specific domains within the overall concept of HRQOL. Those could be 
symptoms of specific diseases such as depression and/or anxiety (e.g. the Hospital Anxiety 
and Depression Scale (74)).  
  
8 
 
Table 1. Health Related Quality of Life measurement in palliative care 
Content of measure: dimensions: 
i Symptoms 
i Physical function 
i Emotional function 
i Cognitive functioning 
i Existential issues (spirituality) 
Proxy ratings: 
i Health-care providers 
i Family members 
Quality of life: 
i Patient and family assessment 
Adapted from Kaasa S.& Loge JH.(75) 
 
1.2.6 Classification in medicine 
A diagnosis, or a classification of a condition, summarizes all relevant medical information 
based on clinical and supplementary examinations and is guiding medical treatment 
decisions, symptom management, and prognostication. A classification system in medicine is 
used to make a diagnosis. The major classification system used for diagnostic purposes is the 
International Classification of Disease (ICD-10) (76) which is used for general epidemiological 
and health management purposes and in clinical practice. In oncology, the tumour, node, 
metastasis (TNM) staging (77) from the Union for International Cancer Control (UICC), 
grading of malignant tumours or histological classification (78), is among the most commonly 
used classification systems and is considered the gold standard for describing the staging of 
malignant tumours (77). The UICC TNM classification system forms the basis for treatment 
decisions and prognostication. According to the UICC TNM system, cancer diseases are often 
classified into four stages (from I to IV). E.g. stage III indicates extensive local and regional 
spread of cancer while stage IV indicates advanced cancer with distant spread of metastases. 
However, not all of the tumours are classified according to UICC TNM classification system. 
For example, brain cancer and lymphomas are classified according to WHO grading system 
(79) and gynaecological cancer is classified according to the International Federation of 
Gynecologists and Obstetricians (FIGO) classification system (80). For depression the 
Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) (81) and the 
International Classification of Mental and Behavioral Disorders10th edition (ICD-10) (82) are 
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commonly used. These classification systems help psychiatrists to measure and quantify 
mental illness though resulting in reliable diagnosis. 
 
1.3 Depression and depressive symptoms 
1.3.1 Prevalence of depression and depressive symptoms 
Vastly different prevalence rate estimates for depression and depressive symptoms in 
cancer patients have been reported (83-87). A recent meta-analysis showed that studies 
using the DSM or the ICD diagnostic systems reported pooled prevalence rates of depression 
of about 16% in oncological, haematological and palliative care settings in patients with 
cancer (88). Hotopf et al. demonstrated in a systematic literature review that the prevalence 
of depression was significantly lower than prevalence of depressive symptoms assessed by 
self-report questionnaire (87). In patients with advanced cancer the prevalence rates of both 
depression and depressive symptoms are ranging from 3% to 58% (4, 5). One study found 
that depressive symptoms increase as death approaches (89), however, other studies report 
no significant changes in depressive symptoms over time (90, 91). The variability in 
prevalence rate estimates may reflect in part the heterogeneity of the population studied 
(44) (addressed in section 1.2.3) and in part the lack of agreed-upon standards for defining 
and assessing depression and depressive symptoms especially in advanced cancer patients 
(92). 
 
1.3.2 Category and dimension 
Depression is characterized by the presence of cognitive, emotional, somatic, and 
behavioural symptoms (81, 82). Depression is first and foremost a disorder of affect 
primarily characterized by lowered mood. Depression can be conceptualised into two major 
ways: as a category (diagnosis) or as a dimension (symptoms) (93). From the categorical 
perspective depression represents a diagnosis of a psychiatric disorder. From the 
dimensional perspective depression can be viewed as the presence of depressive symptoms 
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of different intensity which not fulfil the criteria for a diagnosis. In the following, the two 
concepts will be addressed. 
 
1.3.3 Classification of depression 
Depression as a category represents a group of diagnoses classified as ‘depressive disorders’. 
Examples are ‘major depressive disorder’ (MDD), ‘persistent depressive disorder’ (previously 
known as ‘dysthymia’) or ‘adjustment disorder with depressed mood’. These diagnosis are 
defined by the fulfillment of a set of criteria as proposed by the DSM-5 (81) classification 
system. The ICD– 10 (82) uses the categories which partially correspond with the diagnostic 
categories of depressive disorders. The titles of the categories are sometimes different e.g. 
‘dysthymic disorder’ is used instead of ‘persistent depressive disorder’. 
 
1.3.3.1 Depression according to the DSM-5 
According to the DSM-5 classification system, nine diagnostic criteria constitute the 
diagnosis of MDD (Table 2). Depressed mood and diminished interest or pleasure in activities 
are the two main criteria, and the following seven are the additional ones: weight or 
appetite changes, sleep changes, psychomotor agitation or retardation, fatigue or loss of 
energy, feelings of worthlessness or guilt, diminished ability to think or concentrate or 
indecisiveness, and recurrent thoughts of death or suicidal ideation (Table 2). An MDD is 
established if one of the main criteria and at least four other criteria are present during a 2-
week period (No/Yes). In addition, the symptoms shall be accompanied by a functional 
decline. DSM-5 offers explicit symptomatic criteria allowing for a reliable diagnosis of 
depression (81). A diagnosis of ‘persistent depressive disorder’ is established if the patient 
experiences 3 or more of depressive symptoms including depressed mood and at least two 
additional symptoms, present for at least two years. To fulfil the criteria of having an 
‘adjustment disorder with depressed mood’ two to four of the depressive symptoms are 
present including depressed mood or anhedonia for the last two weeks. It should be 
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accompanied by significant impairment in social, occupational, or other important areas of 
functioning (Table 3). 
 
Table 2. DSM-5 criteria for major depressive disorder (MDD) 
Five or more symptoms present during the last 2 weeks including either question 1 or 2: 
1. Depressed mood  
2. Diminished interest or pleasure in activities (anhedonia) 
3. Weight or appetite changes  
4. Sleep changes  
5. Psychomotor agitation or retardation  
6. Fatigue or loss of energy  
7. Feelings of worthlessness or guilt  
8. Diminished ability to think or concentrate or indecisiveness  
9. Recurrent thoughts of death or suicidal ideation  
The symptoms must persist for most of the day, nearly every day within last 2 weeks leading to functional 
impairment of the patient. American Psychiatric Association (81); DSM-5 = Diagnostic and Statistical Manual of 
Mental Disorders, 5th edition. 
 
Table 3. Diagnostic categories of depression according to DSM-5 
Diagnostic category DSM-5Criteria 
Symptom 
duration 
Major depressive disorder ш5 depressive symptoms, including depressed mood or 
anhedonia, causing significant impairment in social, 
occupational, or other important areas of functioning 
ш 2 weeks 
Persistent depressive 
disorder 
3 or 4 symptoms, including depressed mood, poor appetite or 
overeating, insomnia or hypersomnia, low energy, low self-
esteem, poor concentration or indecisiveness, and 
hopelessness 
ш 2 years 
Adjustment disorder 
 
2-4 depressive symptoms, including depressed mood or 
anhedonia, causing significant impairment in social, 
occupational, or other important areas of functioning 
ш 2 weeks 
American Psychiatric Association (81); DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, 5th 
edition. 
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1.3.3.2 Depression according to the ICD-10 
Based on the ICD-10 classification system, ten diagnostic criteria constitute a diagnosis of an 
MDD (Table 4). MDD is diagnosed if three main criteria are present (low mood, anhedonia 
and fatigue or loss of energy) and in addition, six symptoms qualify as moderate to severe 
depressive episode. The six symptoms include: sleep changes, lack of concentration or 
indecisiveness, low self-confidence, weight or appetite changes, suicide ideation, 
psychomotor agitation or retardation and feelings of worthlessness or guilt. For the 
diagnosis of a milder episode of depression only four symptoms are required. 
 
Table 4. ICD-10 criteria for major depressive disorder (MDD) 
Five or more symptoms present during the last 2 weeks including either question 1 or 2: 
1. Low mood  
2. Diminished interest or pleasure in activities (anhedonia) 
3. Fatigue or loss of energy 
4. Sleep changes 
5. Diminished ability to think or concentrate or indecisiveness 
6. Low self-confidence 
7. Weight or appetite changes  
8. Recurrent thoughts of death or suicidal ideation 
9. Psychomotor agitation or retardation 
10. Feelings of worthlessness or guilt 
 
A comparison of the DSM-5 and the ICD-10 systems is presented in Table 5 showing that 
many of the criteria for MDD are identical. The minimum duration of symptoms is two weeks 
for both the DSM-5 and the ICD-10 classification for MDD. However, the ICD-10 does not 
require the assessment of e.g. impairment of social, occupational, or other areas of 
functioning.  
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Table 5. Diagnostic criteria for major depressive disorder (MDD) in the DSM-5 and ICD-10 
diagnostic systems 
Core symptoms DSM-5 ICD-10 Somatic or non-somatic 
Depressed mood or persistent sadness Yes (core) Yes (core) Non-somatic 
Loss of interest or pleasure in activities (anhedonia) Yes (core) Yes (core) Non-somatic 
Fatigue or loss of energy Yes Yes (core) Somatic 
Sleep changes Yes Yes Somatic 
Diminished ability to think or concentrate or indecisiveness Yes Yes Somatic 
Low self-confidence No Yes Non-somatic 
Appetite changes Yes Yes Somatic 
Recurrent thoughts of death or suicidal ideation Yes Yes Non-somatic 
Psychomotor agitation or retardation Yes Yes Somatic 
Feelings of worthlessness or guilt Yes Yes Non-somatic 
Significant change in weight Yes No Somatic 
 
Diagnosing depression in somatically ill patients may be challenging especially in patients 
with advanced cancer. Common cancer-related symptoms, such as fatigue or loss of energy, 
changes in weight, appetite and sleep changes are also used as diagnostic criteria for 
depression. These symptoms can be attributed to the disease process itself, or be side 
effects of anti-cancer treatment. In order to more precisely diagnose depression also in 
patients with somatic diseases, several suggestions were proposed (Table 7): 
1. DSM-5 recommends the etiologic approach where clinicians are encouraged not to 
include symptoms that are clearly due to a general medical condition. However, it is 
difficult to decide which of the somatic symptoms identified in the DSM criteria are 
attributable to depression and which are due to the cancer disease (81). 
2. Cassem et al. suggested an inclusive approach where all somatic symptoms should be 
included regardless of whether they may or may not be secondary to a physical 
illness (94). 
3. Endicott et al. suggested a substitutive approach that removes somatic symptoms 
from the diagnostic criteria and replaces them with different symptoms that address 
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other non-somatic features of depression such as cognitive symptoms (e.g. 
pessimism and depressed appearance) (95). 
4. Bukberg et al. suggested an exclusive approach eliminating all somatic symptoms 
without any substitution (96).  
 
Table 7. Different approaches to the diagnosis of depression and depressive symptoms in 
cancer patients 
Approach Example of the tool Description 
Etiologic (81) DSM-5 criteria for cancer 
patients 
Determines whether particular symptom is due to medical 
causes before including or excluding in diagnostic criteria for 
depression 
Inclusive (94) RDC (Research 
Diagnostic Criteria) 
Includes somatic symptoms in diagnostic criteria 
Substitutive (95) Endicott Substitutes somatic symptoms with cognitive ones (e.g. 
pessimism, depressed appearance, social withdrawal or 
decreased talkativeness) 
Exclusive (96) HADS (Hospital Anxiety 
and Depression Scale) 
Completely excludes somatic symptoms 
 
1.3.4 Depressive symptoms 
Depression can also be viewed as a dimension (93) representing depressive symptoms. One 
or more of the symptoms constituting a depression diagnosis, may be experienced by the 
patients. However, the intensity and duration of each symptom may not be sufficient to fulfil 
the diagnostic criteria of the DSM-5 or ICD-10 classification systems. The patients may still be 
in need of treatment or special attention (5). In questionnaires, depressive symptoms may 
form a scale together with other symptoms. For example in the EORTC QLQ-C30, depressive 
symptoms together with anxiety form the emotional functioning scale (73). 
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1.3.5 Terminology 
The terminology to describe the two concepts of category and dimension has been used 
interchangeably especially in the literature addressing patients with advanced cancer, for 
example ‘depression’, ‘depressive symptoms’, ‘psychological distress’, ‘emotional distress’ 
and/or ‘emotional functioning’. In the present thesis the term ‘depression’ will be used 
through the thesis to describe the diagnosis of depression, mainly covering the diagnosis of 
MDD as defined by the DSM-5. The term ‘depressive symptoms’ will be used in the thesis to 
cover depression viewed as a dimension. A summary of the conceptual model of depression 
and depressive symptoms is presented in Table 6. 
 
Table 6. Conceptual model of depression and depressive symptoms 
Depression:  
Category/diagnosis (criterion based) 
Depressive symptoms:  
Dimension/symptom (threshold) 
DSM-5 ICD-10 Depressive symptoms present, 
however no diagnosis established. 
Measured by using cut-off scores 
by a certain questionnaire 
x Major depressive disorder 
Presence of 5 or more of 9 
symptoms 
x Major depressive disorder 
Presence of 7 or more of 10 
symptoms 
x Persistent depressive disorder* 
3 or 4 symptoms 
x Adjustment disorder 
2-4 depressive symptoms 
x Dysthymic disorder 
3 or 4 symptoms 
x Adjustment disorder 
2-4 depressive symptoms 
*Persistent depressive disorder is a new diagnosis according to the DSM-5 classification system which includes 
both chronic major depressive disorder and the previous dysthymic disorder. The main reason for this change 
was no evidence for meaningful differences between these two conditions.  
 
1.4 Assessment of depression and depressive symptoms 
In psychiatry, the standard method for diagnosing depression is an interview conducted 
according to the DSM and ICD classification systems (97-99). The interview should be 
administered by a clinician or trained mental health professional, for example a psychologist 
or medical doctor with the relevant professional training. Structured and semi-structured 
diagnostic interviews are commonly used methods for diagnosing depression. The 
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Structured Clinical Interview for DSM Disorders (SCID) (100) is considered as the gold 
standard in psychiatry using the semi-structured manner of interviewing and applying the 
DSM-IV criteria for diagnosis. This interview method was first introduced in the 1970s 
allowing the lay interviewer to obtain a diagnosis close to the one a psychiatrist would 
obtain (97, 98). According to this, SCID became an efficient, user-friendly instrument which 
helped clinicians to make standardized, reliable, and accurate diagnoses. Schedules for 
Clinical Assessment in Neuropsychiatry (SCAN) (101) is another commonly used semi-
structured interview which was created by the WHO aiming to diagnose and measure 
mental illnesses that may occur in adult life. It was not created directly using either ICD-10 or 
DSM-IV; however, it could be used for both systems. The WHO Composite International 
Diagnostic Interview (CIDI) (102) is a fully structured interview used to diagnose mental 
disorders. It was generated in cooperation with WHO and the U.S. Alcohol, Drug Abuse, and 
Mental Health Administration (ADAMHA). The time needed to administer a full structured or 
semi-structured interview is approximately 1, 5 to 2 hours. This may be challenging in clinical 
practice because many patients are frail and require personnel resources. However, it is also 
possible to choose some parts from the interview that are related to specific diagnosis of 
interest which takes shorter time.  
 
1.4.1 Assessment tools for depression and depressive symptoms 
A systematic literature review covering the period from 1966 to 2007, demonstrated that 
106 different assessment tools for depression or depressive symptoms were applied in 
studies in patients with advanced cancer and that a validated diagnostic system was used 
only in a minority of the studies (92). Several of the tools are questionnaires most often 
developed for assessing and monitoring depressive symptoms. The recent European clinical 
guidelines on the management of depression in palliative care recommend systematic 
assessment to improve the identification of depression in patients with advanced cancer 
(103). However, assessment tools are not diagnostic. If a patient has been identified to 
experience depressive symptoms assessed by a certain questionnaire, further assessment 
with a clinical interview is needed to reveal a potential diagnosis. Systematic literature 
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reviews on depression in patients with advanced cancer show that depression-specific, QOL 
and HRQOL assessment tools including items on depression are commonly used (87, 92). 
Some of the most commonly used tools will be described below. 
 
1.4.1.1 Hospital Anxiety and Depression Scale 
The HADS-questionnaire was developed by Zigmond & Snaith in 1983 for assessing 
depressive symptoms and anxiety in a medically ill population, based on patients’ self-report 
(74). This 14-item questionnaire includes seven items on each subscale; depression and 
anxiety respectively rated from 0 (no problem) to 3, however reverse rating of some items 
apples. The responses on this Likert scale are based on frequency of symptoms over the past 
week. The questionnaire does not include all somatic and cognitive symptoms of depression 
according to DSM criteria (104). Four of the items are about anhedonia i.e. one of the major 
diagnostic criteria for MDD in ICD and DSM classification systems. The cut-off score of 7 or 8 
from the total depression sub-scale score of 21 is used to indicate ‘possible’ depression, 
while 10-11 indicative of for ‘probable’ depression. A meta-analysis of the diagnostic validity 
of HADS in cancer and palliative care patients showed that the most frequent cut-off scores 
used for both subscales together was 14-15 resulting in a sensitivity of 85% and a specificity 
of 80% (105). 
 
1.4.1.2 Beck Depression Inventory 
Beck Depression Inventory (BDI) (106) was first developed in 1961 with 21-items, followed 
by two revised versions; BDI-I (107) and BDI-II (108). The questionnaire assesses cognitive 
and somatic symptoms of depression during the last two weeks. This Likert scale can be 
administered by professionals as an interview or as a tool for patients’ self-reports where 
each item is scored from 0 (best possible symptom) to 3 (worst possible symptom). Recently, 
a shorter version of the BDI-II was developed to assess cognitive and affective aspects of 
depression. This was called BDI-Fast Screen (BDI-FS) and includes seven items. According to 
the manual, the interpretations of the scores are the following: 0-3 indicates minimal 
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depression; 4-6 indicates mild depression; 7-9 indicates moderate depression while scores of 
10-21 indicate severe depression (109). 
 
1.4.1.3 The Patient Health Questionnaire - 9 
The Patient Health Questionnaire - 9 (PHQ-9) is a self-report tool which is part of the Primary 
Care Evaluation of Mental Disorders (PRIME MD) instrument (110, 111) (appendix). This 
instrument was originally designed to assess and diagnose specific mental disorders in 
primary care using the DSM diagnostic criteria which consists of two parts: a one page 
questionnaire and a 12-page clinical evaluation guide. The questionnaire includes nine 
symptoms of depression according to the DSM-IV diagnostic criteria (112). This depression-
specific questionnaire is described in more detail in section 3.2.1. 
 
1.4.1.4 Distress Thermometer 
The Distress Thermometer (DT) was developed in 1998 by US National Comprehensive 
Cancer Network (NCCN) as a screening instrument for distress in cancer populations (113). 
This self-report scale is used for screening of psychological distress with a 0 to 10 numerical 
rating scale which has a form of the thermometer and is labelled as “No distress” at 0, 
“Moderate distress” at the midpoint, and “Extreme distress” at 10. The DT also includes 
questions on family and physical problems requiring a dichotomous response (Yes/No). A 
validation study conducted in cancer patients from five different setting showed that a cut-
off score in a single distress thermometer of 4 or more is indicative of distress with 
sensitivity of 80% (against HADS cut-off score of ш15 as a criterion) and specificity of 78% 
(using the BSD-18 cut-off scores of ш10 and ш13) (114). Applying cut-off score of ш4 allows 
identification of patients with a range of problems which are likely to reflect psychological 
distress. The time frame for all questions in the DT is the past week. 
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1.4.2 Tools for assessment of QOL or HRQOL including items on depressive 
symptoms 
Several questionnaires exist for the assessment of QOL and HRQOL (69). Usually one or more 
items are included assessing depressive symptoms. Three of the most commonly used 
questionnaires in palliative care research will be presented as examples in the following. 
 
1.4.2.1 The European Organisation for Research and Treatment of Cancer Quality of 
Life Questionnaire C30 
For cancer patients, the European Organisation for Research and Treatment of Cancer 
Quality of Life (EORTC QLQ C-30) (73) is widely used. This 30-item multidimensional self-
report tool has five functional scales: physical, role, cognitive, emotional and social. It also 
assesses symptoms such as depression, fatigue, pain, dyspnoea, and loss of appetite. In 
addition, it includes a global QOL scale. In this Likert scale the items are scored from 0 to 4 
where 0 represents “Not at all” and 4 represent “Very much” except for two items on overall 
health perception and overall QOL that are scored on a 1-7 scale and together form a global 
QOL scale. The time frame for most questions is the last week.  
 
1.4.2.2 Functional Assessment of Cancer Therapy – General 
The Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire is a self-
report tool developed for cancer patients by Cella at al. in 1993 (115). The latest version of 
the questionnaire (version 4) includes 27-items addressing four dimensions of QOL: physical, 
social, emotional and functional well-being. The questions are scored from 0 “Not at all” to 4 
“Very much” in the Likert scale with the question time frame being the last week. Emotional 
well-being scale includes six questions including: feeling sad, coping with illness, losing hope 
to fight illness, feeling nervous, worry about dying and worry about health deterioration.  
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1.4.2.3 Medical Outcome Study 36-Item Short Form 
The Medical Outcome Study 36-Itam Short Form (SF-36) was developed by Ware and 
colleagues in 1993 which is designed to evaluate general health status (71). This widely used 
36-item questionnaire more specifically assesses and summarizes two main measures, 
mainly, physical health and mental health components. Mental health component includes 
scales on mental health, role-emotional, social functioning and vitality. Mental health scale 
assesses five questions namely if the patient is nervous, has low mood, feels calm and 
peaceful, feels depressed, and happy. It can be used as a self-report tool as well as used by a 
trained interviewer. Some questions need dichotomous (Yes/No) response, others 
categorical with either three categories (1=“Limited a lot”, 2=“Limited a little” or 3=“Not 
limited at all”) or 5-6 categories for response. The score are from 0 to 100 where lower 
scores indicate more disability of the person. The questions mostly assess the past two 
weeks, however some questions are assessing present. 
 
1.5 Risk factors for developing depression or depressive symptoms 
Multiple studies have been conducted in order to identify and examine variables as potential 
risk factors for the development of depression (83). Younger age has been shown to be a 
significant predictor of depression in cancer patients as compared to the older age (6, 116). 
Studies revealed that females in the general population are twice as likely to develop 
depression as compared to males (117-120) and this finding has been confirmed in studies of 
cancer patients as well (Table 5) (7, 121). Studies also show that patients who are single are 
more like to develop depressive symptoms (122), while patients who have less formal 
education (123) experience higher scores of depressive symptoms. In addition to the above 
mentioned socio-demographic characteristics, medical variables and disease-specific 
variables have been shown to be associated with depression. This includes certain cancer 
diagnoses such as pancreatic (8), lung (9, 124), and breast (10) as well as stage of the cancer 
disease (125), and co-morbidities (126). Depression has been shown to be an independent 
predictor of mortality in advanced cancer patients (2, 127). Also, studies show that 
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depressive symptoms are higher in cancer patients with impaired physical functioning (128). 
Some of the risk factors are summarized in Table 8. 
 
Patients with advanced cancer often experience multiple co-occurring symptoms (129) and 
which are related (130). Studies show an association between uncontrolled physical 
symptoms, such as pain and depression (131). Patients with higher pain intensity (132-134), 
or a long duration of untreated pain (133, 135) have more depressive symptoms. This may 
also be due to the lower analgesic effects in patients with depression which should be 
further investigated in clinical studies. Studies show that fatigue which is also a diagnostic 
criterion of depression to be associated with depression (129, 136). Fatigue has been 
reported to be more frequent and severe among depressed than non-depressed patients 
(17, 129). Anxiety is also commonly experienced by patients with advanced cancer. It often 
co-occurs with depression, showing an interdependent nature of these two conditions (137). 
However, anxiety is mostly studied in the symptom level (138). A study by Wilson et al.(14) 
including in- and out-patients with advanced cancer showed that out of 14% who were 
diagnosed with an anxiety disorder 66% also met the diagnostic criteria for depression. In 
addition, patients who experience depression and anxiety report a higher burden of somatic 
symptoms (129).  
 
Table 8. Risk factors for developing depression or depressive symptoms in cancer patients 
Socio-demographic characteristics Medical variables Care issues 
Younger age  Cancer disease Living situation 
Female gender Stage of cancer disease Social support 
Marital status Co-morbidities  
Lower education Survival  
 Performance status  
 Pain  
 Fatigue  
 Anxiety  
 Ongoing treatment of depression  
 Psychiatric history  
 Duration of depressive episode  
 Alcohol/drug abuse  
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The European guidelines for management of depression recommend that a set of specific, 
clinical variables should be assessed when diagnosing depression in palliative care patients, 
in addition to the diagnostic criteria for depression (103). These variables include previous 
and ongoing treatment of depression, psychiatric history, and the duration of the depressive 
episode(s). Information on previous or on-going treatment with antidepressants and prior or 
current psychotherapy are important and relevant variables to assess in patents with 
depressive symptoms in order to have complete medical history. A prior personal or family 
history of a psychiatric diagnosis as well as long duration of the episode increases the risk for 
developing new or subsequent depressive episodes (139, 140). In addition, assessment of 
history of alcohol and/or drug abuse may be important as studies have shown that these 
variables maybe independent predictors of depression (141, 142). 
 
1.6 Treatment 
For the treatment of depression in the general population, national and international 
guidelines have been developed, e.g.by the National Institute for Clinical Excellence (NICE) 
(143), the American Psychiatric Association (APA) (144), and the Norwegian National 
Directorate of Health (145). Guidelines were also published for patients with chronic health 
problems (by NICE) (146). International guidelines for treatment of depression in palliative 
care populations were developed recently (103). All of these recommendations address 
different treatment options for cancer patients such as psychotherapy (cognitive 
behavioural, complementary therapies etc.) and pharmacotherapy (including 
antidepressants, psycho-stimulants). In this thesis, only the use of antidepressants will be 
addressed. 
 
1.6.1 Antidepressant medication 
The NICE clinical guidelines on treatment and management of depression in medically ill 
populations (146) and the European guidelines on management of depression in palliative 
care patients (103) recommend the prescription of antidepressants (ADs) when depression 
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has been diagnosed. Antidepressant medication is an effective treatment for depression as 
diagnosed according to DSM-5 diagnostic criteria in patients without somatic illnesses (147, 
148). Also, in physically ill populations (149) and in palliative care patients (150) the use of 
antidepressants has been demonstrated to reduce the number and intensity of depressive 
symptoms. Furthermore, a recent review concluded that pharmacologic interventions are 
effective in treating depression in cancer patients (11). 
 
The existing guidelines and reviews do not recommend a particular antidepressant drug class 
to be better than another (103, 149, 150). Also, uncertainties exist regarding the threshold 
of severity of depressive symptoms at which antidepressant have benefit (149) and the 
latency period before an effect is to be expected. 
 
1.6.2 Prescription of antidepressants 
The literature suggests that there is an under-prescription of antidepressant medication in 
advanced cancer patients (12-14, 151-153). One of the pioneer studies was conducted in UK 
and published in 1999 (151). It examined the prevalence of antidepressant prescription in 
1046 terminally ill cancer patients admitted to a palliative care unit (151). The study showed 
that only 10% of the patients were given antidepressants. This number was lower than 
anticipated as prevalence rates of depression were higher in this population. This survey was 
followed by several other important studies comparing prevalence of antidepressant use 
with the presence of depression (12-14, 58). One study of 5613 cancer out-patients found 
that 8% of the patients had depression according to assessment by using the HADS 
questionnaire and SCID interview. Only 15% of the patients with a diagnosis of depression 
used antidepressants (12). Another study showed that among a small number of terminally 
ill cancer patients, 18% had a probable depression when assessed by the HADS 
questionnaire and only 32% of these were treated with antidepressants (13). A recent study 
by Lloyd-Williams et al. in 629 advanced cancer patients showed that 32% scored severe 
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depressive symptoms on the Patient Health Questionnaire - 9 (PhQ-9), but only one third of 
the depressed cases received antidepressant medication (15). 
 
The under-treatment of depression among advanced cancer patients may indicate that 
diagnosing depression in this patient population is neglected or challenging for physicians in 
other disciplines than psychiatry. Increased knowledge and awareness about assessment 
and classification of depression and depressive symptoms may improve patient care. When a 
diagnosis of depression has been established, several aspects play a role in the process of 
treatment decision. It is reasonable to assume that physician-related factors play an 
important role, such as previous clinical experience with similar cases, basic knowledge 
about depression diagnosis, antidepressant treatment and psychotherapy, and available 
time and resources. In this thesis, not the physician-related, but the patient-related factors 
associated with the use of antidepressant medication have been investigated. The 
knowledge about factors associated with the prescription of antidepressants may guide 
physicians to identify patients in need of pharmacologic treatment. A recent registry-based 
nationwide study in a Norwegian cancer population by Brelin et al. (154) showed that the 
patient characteristics such as younger age, female gender, lower education, and lower 
income were associated with the use of antidepressants. The general practitioners were 
identified as the main prescribers. Further evaluation and examination of clinical 
characteristics other than cancer diagnosis in that study was restricted by the study design. 
Also, other studies result with controversial finding on disease-related characteristics 
associated with antidepressant use. Therefore, there is a need to conduct studies to identify 
patient characteristics that are associated with the used of antidepressants.  
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2. AIMS OF THE THESIS 
The overall aim of the thesis is to contribute to improve the assessment, classification and 
treatment of depression and depressive symptoms in patients with advanced cancer.  
More specifically the following research questions were asked: 
Paper I 
1. How are populations of advanced cancer patients characterised in studies of 
depression and depressive symptoms? 
 
2. How is depression assessed and classified in clinical studies in patients with advanced 
cancer? 
 
Paper II 
3. What is the prevalence of use of antidepressants usage among advanced cancer 
patients included in an international multicentre study? 
 
4. Which socio-demographic and medical variables are associated with the use of 
antidepressants in advanced cancer patients included in an international multicentre 
study? 
 
Paper III 
5. What is the prevalence of depressive symptoms in Dutch cancer patients in the last 
24 hours of their life according to treating physicians’ ratings? 
 
6. Is there an association between depressive symptoms and different socio-
demographic variables, characteristics of care and symptoms in Dutch cancer 
patients their last 24 hours of life? 
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3. MATERIALS AND METHODS 
3.1 Patients 
The patient populations investigated in paper II and III of the present thesis were advanced 
cancer patients. In paper II the study was cross-sectional involving a convenience sample of 
adult patients with advanced cancer from the European Palliative Care Research 
Collaborative – Computerised Symptom Assessment study (EPCRC – CSA) (n=1048) (155). 
Paper III included patients from the retrospective death certificate study in the Netherlands 
(156) based on the sample of adult cancer patients with non-sudden death and who were 
conscious until death (n=1363). 
 
3.1.1 European Palliative Care Research Collaborative - Computerised Symptom 
Assessment study 
The EPCRC – CSA study was a cross-sectional, international, multicentre study (155). The 
major aim of the study was to develop a computer based symptom assessment tool for key 
symptoms in advanced cancer patients, more specifically pain, cachexia and depression. The 
study involved patients from in- and out-patient units, hospices, and general oncology and 
medical wards from 17 palliative care/oncology centres of the eight participating countries: 
Norway, United Kingdom, Austria, Germany, Switzerland, Italy, Canada, and Australia. The 
data collection was performed from October 2008 to December 2009 by touch-sensitive 
computers which included questionnaires in the English, German, Italian, and Norwegian 
languages, covering all national languages within the study. The major inclusion criteria in 
the CSA study were: patients ш18 years, incurable cancer, including those receiving life-
prolonging treatment, having metastatic and/or advanced loco-regional disease.  
 
In total 1070 patient registrations were extracted from the USB sticks of which 19 were 
excluded due to withdrawal of the informed consent (n=4), and no data was recorded 
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because of technical failure (n=15) (157). Of the remaining 1051 available registrations 1048 
patient records with no missing data on the use of antidepressants were analysed. 
 
3.1.1.1 Data collection in the EPCRC – CSA study 
The data collection consisted of two parts; one to be completed by health care professionals 
and one by the patients (157). The patient and physician assessments were performed on 
the same day. All study coordinators were provided with an instruction booklet describing 
how to perform the registrations. The health care professionals recorded patient 
characteristics (e.g. age, gender, marital status, and living situation), socio-demographic data 
(e.g. education), disease characteristics (primary cancer diagnosis, stage of disease, 
comorbidities), Mini-Mental State Examination (MMSE) (158) for cognitive function, 
Karnofsky Performance Status scale (KPS) (159) for physical performance, current 
medication for pain, provision of care (hospital, nursing home, home care), patient setting 
(in- vs. out-patient) and country. Length of survival was calculated and used as a proxy 
variable for prognosis of the disease. A specific question on the use of ADs, specified as “not 
as adjuvant for pain” was a dichotomous question (No/Yes) registered by health care 
professionals. The patient part consisted of a set of self-report questionnaires on symptoms 
and functioning which included PHQ-9 questionnaire for assessment of depression (157).  
 
3.1.2 Nationwide retrospective death-certificate study from the Netherlands 
A nationwide retrospective death-certificate study was performed in 2005 analogous to the 
previously conducted studies in the Netherlands (160-162). The primary aim of the study 
was to investigate the frequency and characteristics of euthanasia, physician-assisted 
suicide, and other medical acts that may hasten death. These studies were important for 
end-of-life decision making in medical practice in the Netherlands, having a major influence 
on national policymaking and the further development of end-of-life care. In 2005, a follow-
up study was performed to assess the effects of the 2002 Dutch law and changes in end-of-
life care (156). 
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3.1.2.1 Patient sampling 
This epidemiologic survey used the stratified sampling technique. Stratification is the process 
of dividing members of the population into subgroups before actual sampling will take place 
(163). This strategy is used when sub-populations within an overall population vary greatly 
and generally ensures a better representation of the study. The subpopulation also known as 
strata must not overlap. Using the stratified sampling method the final sample is drawn from 
a number of separate strata of the population using either proportionate or 
disproportionate random sampling technique (164). The disproportionate stratified random 
sampling ensures that reasonably precise estimates are obtained for each stratum (163, 
164). 
 
A stratified sample of deaths was drawn from the central death registry of the Statistics 
Netherlands (www.cbs.nl) which receives death certificates of all deaths in the country. All 
43,959 deaths that occurred between 1 August and 1 November 2005 were assigned to one 
of the five strata, which was denoted 1 to 5. When the cause of death was one in which it 
was clear that no physician's assistance in dying could have been provided (e.g. instant death 
from a traffic accident), the death was assigned to stratum 1. The cases from stratum 1 were 
retained in the sample, but no questionnaires were sent out to attending physicians. On the 
basis of cause of death all other deaths were assigned to strata 2 to 5, with each stratum 
having a higher likelihood of a medical end-of-life decision preceding death: when this 
decision was unlikely (e.g. acute myocardial infarction or aneurism) cause of death was 
allocated to stratum 2, when this decision was possible (e.g. heart failure or Parkinson’s 
disease) to stratum 3, and when this decision was more probable (e.g. cancer) to stratum 4. 
When the likelihood that a physician's assistance in dying had been provided was likely to be 
high, and when a physician had noted on the death certificate that they had actively ended 
the life of the patient (e.g. euthanasia) the death was assigned to stratum 5. The final sample 
in the dataset contained randomly selected half of the cases in stratum 5, 25% of the cases 
in stratum 4, 12.5% of those in stratum 3, 8.3% of those in stratum 2, and all cases in stratum 
1 (4.2%). 
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3.1.2.2 Data collection 
For all sampled cases from strata 2 to 5 for which the cause of death did not preclude from 
physician assistance in dying and who had filled in the death certificate before or at the time 
of death all attending physicians were mailed questionnaires (6860) with a letter signed by 
the Chief Inspector for Health Care and the president of the Royal Dutch Medical 
Association. The letter included name and date of birth of the diseased person. This 
information allowed the physician to identify the patient and look up the medical file. In case 
the physician filling in the death certificate was not the attending physician, he or she was 
asked to forward the questionnaire to the actual attending physician or return it back. 
Questionnaires were sent out as soon as the corresponding death certificate were included 
in the sample (i.e., as soon as they reached the central administration). Thus, the time 
between death and sending out the corresponding questionnaire was limited to an average 
of one to two months.  
 
3.1.2.3 Population 
Out of 6860 questionnaires that were mailed to physicians, 5342 were returned with the 
response rate of 77.8%. For the present analysis cases were excluded if: (a) the physician had 
first patient contact after patient’s death, (b) the patient died suddenly or unexpectedly 
according to the physician, (c) the patient was less than 17 years old, (d) the cause of death 
was other than cancer, and if (e) the patient was unconscious in the last days of life. This 
resulted in a sample of 1521 patients, in which missing information on depressive symptoms 
occurred in 10.4%. Thus, the final sample in paper III consisted of 1363 cases. More details 
on the selection process are presented in appendix.  
 
3.2 Assessment tools 
3.2.1 Patient Health Questionnaire - 9 
The PHQ-9 questionnaire was designed and validated in medically ill (165) as well as 
palliative care populations including both non-cancer and cancer patients (166). The meta-
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analysis on 14 studies validating the PHQ-9 against depression in primary care, medical 
outpatients, and specialist medical services showed a sensitivity of 80% and a specificity of 
92% (167). Including nine symptoms of depression from DSM-IV, this short and reliable tool 
applies a diagnostic algorithm for diagnosing depression (MDD). A diagnosis of depression is 
likely if five out of nine depressive symptom criteria have been present at least “more than 
half of the day” in the last 2 weeks, and if one of the symptoms is either depressed mood or 
anhedonia. One of the nine symptom criteria (“Thoughts that you would be better off dead 
or of hurt yourself in some way”) counts if present at all, regardless of duration. For each 
item the patient is asked to indicate whether they have been bothered by this symptom ‘not 
at all’, ‘several days’, ‘more than half the days’ or ‘nearly every day’ in the last two weeks 
where each response is rated on a scale from 0 to 3. As a severity measure, total scores can 
range from 0 to 27 with 27 as most severe. Validated cut-off scores are 5, 10, 15, 20 
referring to minimal, mild, moderately severe, and severe depressive symptoms (111).  
 
3.2.3 Karnofsky Performance Status scale 
Karnofsky Performance Status (KPS) is a scale used to measure physical performance and 
functional impairment of the patient (appendix) (159). This tool is frequently used in 
oncology and palliative care settings to assist treatment decisions and prognostication. The 
scores may range from 0 to 100% where higher scores indicate that the patient is better able 
to carry out daily activities (159). Poor Karnofsky score has been demonstrated to be a 
predictor of shorter survival in cancer patents (168, 169). It has also been shown that 
patients with lower performance status experience more severe depressive symptoms (170, 
171). 
 
3.2.4 Survey questionnaire in paper III 
The four-page questionnaire (appendix) applied in paper III was developed in the 
Netherlands by the researchers at VU University Medical Center and Erasmus Medical 
Center. It included information on care received by the patient such as medical specialty of 
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the attending physician, and whether other health care providers were involved in the care 
of the patient (e.g. pain specialist/palliative care consultants) in the last month of life. 
Moreover, the prevalence and intensity of the following symptoms were rated by the 
physician who signed the death certificate; depression, pain, vomiting, fatigue, dyspnoea, 
confusion, and anxiety in the last 24 hours before death. Symptom intensity was registered 
by a rating scale ranging from 1 = no symptoms to 5 = very severe symptoms. Socio-
demographic characteristics (e.g. gender, age at death, marital status, place of death) and 
underlying cause of death were captured from the death certificates which were linked to 
the questionnaires. 
 
3.3 Systematic literature reviews 
Systematic literature reviews are retrospective, descriptive research studies aiming to 
provide a comprehensive body of knowledge on a particular subject, research question, 
and/or evidence for a particular intervention and reduce bias (172, 173). It is the explicit and 
systematic approach that distinguishes systematic reviews from traditional narrative reviews 
and commentaries. Systematic literature reviews, as compared to narratives and 
commentaries, use a systematic and reproducible methodology to identify primary studies 
that fit with a set of pre-defined criteria (172, 174). As part of the methodology, an explicit 
literature search strategy is applied with defined keywords to be used in relevant databases. 
Explicitly pre-defined criteria are used for selection of relevant studies for 
inclusion/exclusion. Critical appraisal of the selected papers is also conducted and results are 
summarized in a quantitative and/or qualitative approach. In 2009 the PRISMA Statement 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) was first published to 
guide researchers in planning, completing, and reporting systematic literature reviews and 
meta-analysis (172). Paper I was conducted according to these guidelines aiming at 
investigating how populations of advanced cancer patients were described and reported in 
clinical studies of depression and depressive symptoms and to describe the assessment and 
classification methods applied.  
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3.1.1 Systematic literature search 
The databases PubMed, CINAHL (through EBSCOhost), PsycINFO and Embase (through 
OvidSP) were searched for relevant studies. The searches covered the years 2007 through 
2011 with the last search date being January 3, 2012. The search strings were designed for 
each database using both free-text and controlled vocabulary (e.g. MeSH, CINAHL Headings, 
APA Thesaurus, EMtree), and consisted of combinations of predefined terms representing 
“depression”, “palliative care” and “advanced cancer”. The search strings of all four 
databases are presented in appendix. 
 
3.1.2 Selection of relevant papers 
Titles, abstracts and keywords of the identified citations were independently screened by 
two authors to judge their potential relevance. Then, citations identified as possibly relevant 
by two readers were retained for full-text reading, while those selected by only one were 
discussed before a decision about inclusion or exclusion was made. The full-text papers were 
reviewed and retrieved by two of the authors independently. Any discrepancies between the 
reviewers' selections were discussed to obtain consensus, or a third author was consulted. 
 
The study used the following predefined inclusion criteria: 1. clinical study with adult 
advanced cancer patients (ш18 years), and 2. primary study outcome including the term 
depression or depressive disorder. The exclusion criteria were: non-English publications, 
reviews, commentaries, case-reports, publications addressing tool development (e.g. 
validation studies), and studies with non-cancer patients included in the sample (Table 9). 
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3.1.3 Extraction 
Data extraction from the full-text papers was conducted according a predefined checklist. 
The checklist was based upon the content of the EAPC basic dataset (55) and on systematic 
literature regarding depression in advanced cancer patients (92). It was holding a set of 
items recommended for use when reporting results from studies in palliative cancer care, 
including socio-demographic, disease-related, and patient-reported variables. The checklist 
also contained the specific variables of relevance for diagnosing and treating depression, 
such as psychiatric history, previous depressive episodes, and on-going treatment for 
depression (pharmacological and non-pharmacological) as well as information on methods 
used for assessment and classification (i.e. diagnostic system) of depression (92). Method of 
assessment of depression was recorded as ‘classification of depression based on a diagnostic 
system’ and ‘classification of depression independent of a diagnostic system’. 
 
Overview of variables presented in all three papers including descriptive statistics is shown 
in this section as Table 10. 
 
Table 10. Overview of the variables used in the three papers 
 Paper 1 
Syst. lit. review 
Paper 2 
Cross-sectional 
Paper 3 
Retrospective 
Socio-demographic 
Age 9  9  9  
Gender 9  9  9  
Ethnicity 9    
Marital status 9  9  9  
Education 9  9   
Religion 9    
Medical variables/disease-specific information 
Primary cancer diagnosis 9  9   
Time since diagnosis 9    
Stage of cancer disease 9  9   
Metastasis 9  9   
Site of metastasis 9    
Co-morbidities 9  9   
Expected survival 9  Not inclusion criterion Mortality study 
Real survival 9  9   
Weight loss 9    
Performance Status 9  9   
Cognitive function 9  9  9  
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Treatment 
Present anti-cancer treatment 9    
Medication 9  9   
Caregiver issues 
Living situation (alone) 9  9   
Social network 9    
Attending physician specialty   9  
Professional caregivers involved   9  
Setting  
Place of care/place of death  9  9  9  
Provision of care (in-/out-patient) 9  9   
Depression-specific information 
Use of antidepressants 9  9   
Psychotherapy 9    
Psychiatric history 9    
Duration of depressive episode 9    
Previous depressive episode 9    
History of alcohol/drug abuse 9    
Symptoms 
Pain   9  
Vomiting   9  
Fatigue   9  
Dyspnoea   9  
Confusion   9  
Anxiety   9  
 
Table 8 continued 
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3.4 Statistical procedures 
The statistical software IBM SPSS (Statistical Package for Social Sciences) version 19.0 for 
Windows (IBM Corporation, Armonk, NY, USA) was used for the statistical analysis in paper I 
and III. In paper II the STATA 12.0 software (STATA Corp., 2012, College Station, TX, USA) was 
used. 
 
3.4.1 Bivariate association analysis 
In order to study the relationship between independent variables potentially associated with 
the dependent variable in paper II and III the following bivariate association analyses were 
performed. 
Paper II: Bivariate association between the use of antidepressants and other variables was 
examined with simple logistic regression models (175), as the dependent variable (use of 
antidepressants, No/Yes) was binary. Independent variables investigated were: gender, age, 
living situation, education, primary cancer diagnoses, patient setting, stage of cancer 
disease, medication for pain, KPS, number of co-morbidities, and survival. Continuous 
variables (age, KPS, co-morbidities and survival) were categorized. In order to test for 
sensitivity to variables categorization, the model selection was replicated using continuous 
variables. The set of variables showing statistically significant associations with the 
dependent variable in the logistic regression (95% CI of the Odds Ratio (OR) not containing 1) 
were further examined in a multiple regression analysis. 
Paper III: Bivariate associations between variables were tested with chi-square test (ʖ2) 
(176). The dependent variable was originally registered in the questionnaire as a rating scale 
from 1 to 5, where 1 = “not depressed” and 5 = “very depressed”. This scale was further 
recoded into three categories: 1 = no, 2-3 = mild/moderate and 4-5 = severe/very severe 
depressive symptoms which were chosen as a dependent variable. The independent 
variables that were tested for potential associations were gender, age, marital status, 
medical specialty of attending physician, caregivers involved in the care of the patient (pain 
specialist/palliative care consultant, psychiatrist/psychiatrist, spiritual caregivers, volunteer), 
and symptoms such as pain, vomiting, fatigue, dyspnoea, confusion and anxiety. Symptoms 
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were also registered as a rating scale which was also recoded into three categories. P-value 
of <0.05 was chosen for statistical significance.  
 
3.4.2 Multivariate association analysis 
Multivariate association analysis is used to study relationship between the dependent 
variable and more than two independent variables (177). These regression analysis can be 
multiple logistic (dependent variable has two categories) and multiple multinomial logistic 
(dependent variable has three or more categories) depending on the nature of the outcome 
variable.  
Paper II: Multivariate association between variables were studied with multiple logistic 
regression models with backward elimination method for independent variable selection. 
The chi-square test with the p-values of <0.05 was used for excluding variables from the 
analysis. The model was adjusted by country to account for a potential lack of independency 
among observations from the same country. The regression model was not adjusted by the 
level of depression as measured by PHQ-9 due to the potential influence by the dependent 
variable. Nagelkerke Pseudo R2 and area under the Receiver Operating Characteristic (ROC) 
curve (C statistics) (178) were used to examine overall performance and discrimination 
capability of the final model; R2 is used to assess goodness of fit in linear regression model as 
it represents the proportion of variance in the outcome variable that is explained by the 
independent variable. C statistics is an indicator of discriminative capability of the model. 
Values range from 0 to 1 where 50% represents a baseline value of predictive capability of a 
chance which is a predictive capability of the empty model. Values can be interpreted 
following Hosmer and Lemeshow ʖ² statistic (181). Accordingly, the model is considered to 
have outstanding discrimination when C ш 0.9, excellent discrimination if 0.8 ч C < 0.9, 
acceptable if 0.7 ч C < 0.8, and no discriminative capability (discriminant capability of an 
empty model) if C = 0.5. 
Paper III: Multivariate association between variables were studies with multiple multinomial 
logistic regression models. The main reference category from the dependent variable was 
chosen to be “no depressive symptoms” as we were interested in physicians’ ratings of 
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depressive symptoms as a study outcome. In the first step of this analysis, all independent 
variables were entered into the model, except place of death. This variable was left out from 
the analysis because of its high correlation with medical specialty of the attending physician 
(clinical specialists work in hospitals, elderly care physicians in nursing homes, and general 
practitioners attend to patients at home and in residential homes). The backwards stepwise 
approach was used to exclude variables from the model. Variables showing a statistically 
significant association with one or more of the categories of the dependent variable 
(mild/moderate depressive symptoms, severe/very severe depressive symptoms or both) 
remained in the final model. P-values <0.05 were considered to indicate statistical 
significance.  
 
3.4.3 Weighting and standardisation procedures 
When conducting a survey, it is paramount to have a representative sample of the 
population. However, this is not always possible. In order to overcome this limitation 
different statistical methods are applied in the data: sampling weights and standardisation. 
Sampling weights are used to adjust results for imperfections in the sample that might lead 
to bias and other problems between the sample and the reference population. Two of the 
most common types of sample weights are used in the survey data: design weights and non-
response weights (179, 180). Design weights (also referred to probability weights) are used 
to compensate for over- or under-sampling of specific cases or for specific study design such 
as disproportionate stratification in order to correct for their unequal probabilities of 
selection (179). Non-response weights are used to compensate for the fact that cases with 
certain characteristics (e.g. age, sex) are not as likely to respond to the survey. Survey non-
response can produce biased estimators when respondents and non-respondents differ 
significantly on survey variables (180). In addition, standardisation of the rates is needed in 
order to produce comparable measures between groups by removing effect of major 
confounders. By using the direct standardisation method rates of different characteristics 
from each of the sample under study are applied to a reference population (181). 
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All statistical procedures in paper III excluding the multiple multinomial logistic regression 
analysis took into account the weighting procedure to adjust for:(1) differences in the 
percentages of deaths sampled from each stratum (design weight), (2) differences in 
response rates in relation to characteristics such as age, sex, marital status, region of 
residence, and cause of death of the patient (non-response weight). After adjustment, the 
percentages were (3) scaled in proportion for random sampling deviation to cover a 12-
month period, to reflect all deaths (n=136,402) in the Netherlands in 2005 (standardisation). 
 
Weighting factors for the data in paper III were calculated by Statistics Netherlands in the 
following steps. First, the inverse of the percentage of deaths sampled from each stratum 
was taken. The resulting factor was multiplied by a second factor that was calculated by 
dividing the sampled number of deaths by the number of deaths for which we received a 
questionnaire from the physician for each combination of characteristics of patients (sex, 
age, marital status, cause of death, region of residence and place of death). The weighting 
factors that resulted from step 1 and 2 were multiplied by a factor that was calculated in the 
third step, by dividing the actual number of cases in the population of deceased persons in 
2005 for each combination of characteristics of patients by the number of cases from the 
first two weighting steps (156). 
 
3.5 Ethics 
Study II was performed according to the Helsinki declaration (182). Approval from Ethical 
Committees and other regulatory bodies were obtained as necessary in each country. 
Written informed consent was obtained from all patients. In paper III the data collection 
procedure allowed identification of physician and patient by the researchers (Statistics 
Netherlands). The Ministry of Justice gave a guarantee in the accompanying letter to the 
questionnaire that no physician could be prosecuted on the basis of information given to the 
researchers. According to Dutch legislations, there was no need for ethical committee 
approval as this procedure was allowed through a special low on Statistics Netherlands.  
41 
 
4. RESULTS AND SUMMARY OF PAPERS 
4.1 Paper I 
“How are the patient populations characterized in studies investigating depression in 
advanced cancer? Results from a systematic literature review” 
 
Prevalence rates of depression and depressive symptoms in patients with advanced cancer 
vary considerably from 3% to 58%. This variability may be due to the heterogeneity of the 
populations studied but also the lack of agreed-upon standards for defining and assessing 
depression in this patient group. Thus, adequate sample descriptions and consistent use of 
measures are needed in order to generalize research findings and apply these in clinical 
practice. The aims of the study were: 1. to investigate which clinically important variables 
were used to describe the samples in studies of depression and depressive symptoms in 
advanced cancer patients, and 2. to examine the methods used for assessing and classifying 
depression and depressive symptoms in included studies.  
 
A systematic literature search covered the years from 2007 till 2011 yielding 1669 potentially 
relevant citations from four bibliographic databases. Among those, 125 were included for 
full-text reading and 59 papers were retained. The most frequently reported variables from 
the EAPC basic dataset were age (93%), gender (90%), principal cancer diagnosis (97%), and 
stage of cancer disease (95%) followed by performance status (65%), anti-cancer treatment 
(59%), place of care (91%) and provision of care (83%). Less frequently reported variables 
were education (42%), cognitive function (38%), time since diagnosis (27%), medication 
(27%), living situation (17%), ethnicity (15%), additional diagnosis (14%), site of metastasis 
(10%), and weight loss (3%). Depression-related variables were rarely reported. Psychiatric 
history and previous depressive episodes were reported in 17% and 12% of the studies, 
respectively. Information on antidepressant medication was recorded in 17% of the studies. 
Twenty-five per cent of the studies used validated diagnostic systems for classifying 
depression such as the DSM and ICD classification systems with structured and semi-
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structured interviews. Seventy-five per cent of the studies did not use a validated diagnostic 
system; however self-reported tools such as the Hospital Anxiety and Depression Scale (48%) 
and different versions of Beck Depression Inventory (25%) were commonly used.  
 
The findings from this systematic literature review showed that the current practice for 
describing sample characteristics (e.g. socio-demographic, medical as well as depression-
specific) and assessment methods for depression varied between studies in patients with 
advanced cancer. In addition, clinical information related to depression (e.g. antidepressant 
use, different types of psychotherapy) in studies with advanced cancer patients were lacking. 
 
There is a need to define a more standardized way of reporting sample characteristics and 
depression-related variables in clinical studies investigating depression, in order to enhance 
the generalizability and utility of findings. 
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4.2 Paper II 
“The use of antidepressants in patients with advanced cancer - results from an 
international multicentre study”  
 
Depression is burdensome psychiatric disorder in advanced cancer patients. The use of 
antidepressants in this patient population is shown to be effective treatment for major 
depressive disorders and depressive symptoms. However, depression is often not recognised 
and thereby inadequately treated. The study aim was to explore the use of antidepressants 
in a large sample of advanced cancer patients and to identify socio-demographic and 
medical variables that are associated with their use. 
 
For this study, data from the European Palliative Care Research Collaborative – 
Computerized Symptom Assessment study (EPCRC – CSA) were used, which was an 
international, cross-sectional, multicentre study including 17 centres across six different 
countries in Europe plus two in Australia and Canada respectively. Healthcare professionals 
registered patient and disease-related characteristics. A dichotomous score (No/Yes) was 
used to assess current use of antidepressants other than as an adjuvant for pain. Self-report 
questionnaires from patients were used for the assessment of functioning and symptom 
intensity in this cross-sectional study. 
 
Out of 1051 patient registrations in the EPCRC – CSA study, 1048 patients were included in 
the present analysis; those with complete data on antidepressants use. Of these, 48% were 
females, mean age was 62 years (SD 12.3), the majority of patients were receiving in-patient 
care and 85% had metastatic disease. Prevalence of antidepressant use by the sample was 
14%. As a result of multivariate logistic regression analysis (Figure 2) younger age (OR 2.46; 
CI 1.32-4.55), female gender (OR 1.59; CI 1.09-2.33), current medication for pain (OR 2.68; CI 
1.65-4.33), and presence of three or more comorbidities (OR 4.74; CI 2.27-9.91) were 
associated with antidepressant use other than as adjuvant for pain. Disease-related variables 
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(diagnoses, stage of disease, Karnofsky Performance Status scores and survival length) were 
not associated with the use of antidepressants. 
 
Figure2. Results from multivariate logistic regression analysis 
 
 
 
These results from a large international cross-sectional study showed that the prevalence of 
antidepressant use in patients with advanced cancer was relatively low as compared to 
other studies (14%) and that the use was associated with certain socio-demographic and 
disease characteristics (female gender, younger age, medication for pain, and multiple 
comorbidities). However, there is still a lack of information on which variables are guiding 
physicians in prescribing antidepressant medication.  
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4.3 Paper III 
“Depressive symptoms in the last days of life of patients with cancer: a nationwide 
retrospective mortality study” 
Depressive symptoms are common in cancer patients. Different socio-demographic 
characteristics and symptoms such as fatigue and pain have been identified as being 
associated with depressive symptoms leading to impaired QOL. Patients’ self-report of 
symptoms is standard in palliative care; however, during the last days of life this may not 
always be possible. Thus, proxy ratings of patients’ symptoms by health care providers may 
be a feasible option. The aim of this study was to examine prevalence of physician reported 
depressive symptoms in the final 24 hours of cancer patients’ life, and their association with 
other symptoms, socio-demographic and care characteristics. 
 
In this nation-wide retrospective mortality study in the Netherlands, 6860 questionnaires 
were mailed to physicians who signed the death certificates, and 5342 (78%) were returned. 
In the present analysis only adult cancer patients with non-sudden death were included 
(n=1363). 
 
The data showed that 72% of the patients were 65 years or above, 57% were male and 48% 
died at home. Depressive symptoms were registered in 38% of the patients in total, and as 
mild/moderate in 32% and as severe/very severe in 6%. The odds for being assessed to have 
mild/moderate depressive symptoms were higher for the younger patients as compared to 
patients who were 80 years or more (OR 0.70, 95% CI 0.50-0.99). 
 
The odds for being assessed to have severe/very severe depressive symptoms were higher 
when the attending physician was a physician working in a nursing homes in the Netherlands 
as compared to a clinical specialist or general practitioner (OR 4.18; 95% CI 1.48-11.76). 
Involvement of pain specialists or palliative care consultants and psychiatrists or 
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psychologists was associated with more ratings of severe or very severe depressive 
symptoms. Fatigue and confusion were significantly associated with mild/moderate 
depressive symptoms, while anxiety was associated with both mild/moderate and 
severe/very severe depressive symptoms.  
 
In summary, more than 1/3 of the cancer patients were categorized with depressive 
symptoms during the last 24 hours of life as reported by their attending physicians. Multiple 
symptoms and depressive symptoms in particular, in cancer patients at the end of life still 
call for special attention to improve care for dying patients. 
  
47 
 
5. DISCUSSION 
5.1 Interpretation and discussion of main findings 
The main aim of this PhD project was to contribute to improve characterisation, assessment 
and treatment of depression and depressive symptoms in advanced cancer patients. The 
systematic literature review (paper I) demonstrated that there is an unsystematic and 
inconsistent reporting of clinical core variables to describe patient populations in studies on 
depression and depressive symptoms in patients with advanced cancer. Further, most 
studies did not provide information about depression-related variables (e.g. use of 
antidepressants, previous depressive episodes) which are important for the interpretation of 
study results and for clinical practice. Validated diagnostic tools for depression were rarely 
used and the use of assessment methods varied greatly. Results from an international multi-
centre study (paper II) demonstrated that 14% of advanced cancer patients used 
antidepressants. The use of antidepressants was associated with characteristics such as 
female gender, younger age, medication for pain and multiple co-morbidities. In a nation-
wide death certificate study (paper III) the treating physicians reported retrospectively that 
more than one-third of cancer patients had depressive symptoms during the last 24 hours of 
life. An association was found between the presence of depressive symptoms as rated by the 
physicians and the following variables: age, specialty of attending and treating physicians, 
involvement of more than one specialist in the care of the patients (e.g. pain and/or 
palliative care consultant), and symptoms such as fatigue, anxiety and confusion. 
 
5.1.1 Socio-demographic, disease and depression-specific information including subjective 
symptoms important for assessment, classification and treatment of depression 
For the proper understanding of the patients populations in clinical studies in general, it is 
paramount to assess, describe and report core patient characteristics (52). However, 
according to the results presented in paper I, the description of the patient samples in 
studies addressing patients with advanced cancer and depression/depressive symptoms 
varied greatly. These findings are in line with results from a recent systematic literature 
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review addressing how palliative care cancer populations were described in randomized 
controlled trials (52). Another, also recently published systematic literature review, by Van 
Mechelen et al. described cancer as well as non-cancer populations in randomised 
controlled trials (51). Six variables were proposed to describe a palliative care population: 
diagnosis, disease progression, life expectancy, clinical settings, intervention, and outcome 
(51). The EAPC basic dataset was introduced recently by the EAPC RN (53), PRC (18) and the 
PRISMA project (54) recommending a set of core variables to be used in clinical studies of 
palliative care cancer patients (55), representing an important step towards more 
standardization and basis for improved generalizability. The EAPC basic dataset requires 
additional and study specific variables related to the disease group, treatment, and the 
defined primary and secondary outcomes of the study. For studies addressing depression in 
patients with advanced cancer it is paramount to register information related to depression. 
In the following, characteristics relevant for the management of patients with advanced 
cancer and depression or antidepressant use identified in paper I, II and III will be addressed 
and are summarised in Table 11. 
 
5.1.1.1 Socio-demographic characteristics 
Patients’ age was reported in 93% of the studies in paper I, placing this variable among the 
most frequently reported variables in the investigated publications. Younger age has been 
shown to be associated with increasing depressive symptoms in advanced, metastatic cancer 
patients (6). However, in paper III we found that patients who were 80 years and older had 
significantly fewer depressive symptoms compared to those who were 17-65 years old. This 
result from paper III is inconclusive and difficult to interpret as they cannot directly confirm 
results from other studies showing that younger age may be associated with depression. An 
association of older age and antidepressant prescription in the general population is well 
known (183, 184) and might be explained by the acceptance of depressive symptoms by 
health care providers as a normal part of the aging process. However, in paper II 
antidepressant use was more common in younger patients, as shown in a registry-based 
study from Norway (154). This might indicate an increasing awareness of health care 
providers that younger patients with metastatic cancer are at higher risk of developing 
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depression than the older age group (6) when those patients are facing life-threatening 
disease early in life.  
 
Female gender has been found to be associated with depression in the general population 
(117, 119, 120) and in cancer patients (7, 121). In paper II, the prevalence of antidepressant 
use was higher in women than in men, which was consistent with previous findings in a 
general population (185) and in a cancer population (186). One of the explanations could be 
that women disclose symptoms more commonly than men and therefore seek help more 
often. However, the association of gender with the use of antidepressants in paper II was 
weak and the results regarding the association of gender with depression in cancer patients 
differ in the literature. A cross-sectional study including patients with different cancer types 
showed no gender differences (9) while other cross-sectional studies including advanced 
cancer patients showed male gender to be associated with depression (166, 187). In paper 
III, depressive symptoms as reported by physicians were not associated with gender when 
testing bivariate associations. This could be explained by the fact that patients in paper III 
were facing the last 24 hours of life and therefore, gender differences disappeared with the 
terminal stage of cancer disease.  
 
Marital status was reported in 49% of the studies. A longitudinal study including 190 patients 
showed that being unmarried is associated with developing depressive symptoms in breast 
cancer patients (122). This finding may point to the importance of assessing and providing 
emotional support especially in cancer patients with limited social network. However, this 
could not be supported by results obtained in paper III. For paper II, we used the variable 
‘living situation’ with response ‘alone vs. not alone’ as a substitute of ‘marital status’, but 
this variable was not significant either.  
 
Educational level was reported in 42% of the studies in paper I. The association between 
education and depression and use of antidepressants are variable in cancer population. 
50 
 
Some of the studies show no association between educational level and depressive 
symptoms (188). Some of the authors also showed education to be associated with the use 
of antidepressants in cancer patients. A cross-sectional study showed that cancer patients 
with higher education receive less antidepressants (154), while a longitudinal study including 
only breast cancer patients did not show any association between education and use of 
antidepressants (189) as was the case in paper II.  
 
Table 11. Factors associated with the dependent variables in paper II and paper III 
Paper I Paper II 
Dependent variable: 
Use of 
antidepressants 
Paper III 
Dependent variable: Depressive 
symptoms 
Often 
reported: 
Age Younger age Older age 
Gender Female gender Not significant 
Primary cancer diagnosis Not significant Not used 
Stage of cancer disease Not significant No info 
Performance status Not significant No info 
Present anticancer 
treatment 
No info No info 
Place of care Not tested Not tested 
Provision of care Not significant No info 
Less often 
reported: 
Ethnicity No info No info 
Marital status Not tested Not significant 
Education Not significant No info 
Religion No info No info 
Time since diagnosis No info No info 
Metastases Not significant No info 
Site of metastases Not tested No info 
Co-morbidities 3 or more co-
morbidities  
No info 
Expected survival No info No info 
Real survival Not significant No info 
Weight loss No info No info 
Cognitive function Not tested No info 
Medication Medication for pain 
significant 
No info 
Living situation Not significant No info 
Social network No info No info 
Use of antidepressants Dependent No info 
Different types of 
psychotherapy 
No info No info 
Psychiatric history No info No info 
Duration of present 
depressive episodes 
No info No info 
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Previous depressive 
episodes 
No info No info 
History of alcohol and/or 
drug abuse 
No info No info 
   Physicians working in the nursing homes 
(elderly care physicians) 
Pain specialist/palliative care consultant 
Psychiatrist/psychologist 
Fatigue 
Anxiety 
Confusion 
   Not significant:  
x Volunteer  
x spiritual caregiver  
x pain 
x vomiting 
x dyspnoea 
Table 11 continued  
 
5.1.1.2 Disease-specific information 
Patients with chronic medical conditions such as cancer, diabetes mellitus or cardio-vascular 
disease have a greater risk of developing depression then the general population (190). 
Furthermore, patients with certain cancer diagnoses such as breast (9), lung (9) and 
pancreatic cancer (191) have a greater risk of developing depression compared with patients 
having cancer of other organs. Reasons in patients with breast cancer may include long 
disease duration and loss of femininity (192), while for lung and pancreatic cancer this could 
be bone metastases, rapidly progressing disease and high symptom burden (193). In 
addition, a cross-sectional study showed that depression is more likely to develop in patients 
having a more advanced stage of cancer disease at the time of diagnosis (132). More 
advanced disease is in general associated with less hope for the future and with higher rates 
of depression (132). Therefore, assessment and reporting of the cancer diagnosis and stage 
of the cancer disease is regarded as important both in research and in clinical practice 
related to cancer patients and depression. Cancer diagnosis and stage of cancer disease was 
reported in 97% and 75% of the studies (paper I). The patients in paper II had different 
cancer diagnoses and 85% of them had metastatic disease. The results from paper II showed 
no association between cancer type and the use of antidepressants, nor with stage of 
disease and use of antidepressants, different from other studies on depression (90, 91). In 
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paper III, all patients had cancer; however, type of cancer was not available. Detailed 
information on stage of cancer disease was also lacking, but all patients were assessed in 
their last days of life. 
 
Studies show higher levels of depression in patients with chronic co-morbid conditions (126). 
Therefore, information on additional diagnosis is another important variable to be assessed 
and reported in depression studies. Comorbidity was reported only in 14% of the studies 
included in paper I. In paper II, patients with three or more chronic co-morbid conditions 
were four times more likely to receive antidepressants compared with patients without co-
morbidities. This finding confirms results from a retrospective study by Ashbury et al. 
showing higher odds of antidepressant use among community cancer patients with co-
morbidities (194). This could be explained by the fact that health care providers may pay 
more attention to the patients with multiple conditions and be well aware that they could 
develop depression and therefore offer these patients antidepressants. 
 
Depression may be an independent predictor of mortality in cancer patients (2, 195). Real 
survival in paper I was reported in 25% of the studies. In paper II, a survival time of more 
than 91 days was recorded in 65% of the patients. No association between survival and the 
use of antidepressant was shown which is in line with prospective cohort studies of patients 
with newly diagnosed non-small cell lung cancer (196, 197). 
 
Physical performance status is used for prognostication and measurement of functional 
impairment of cancer patients. Studies show that poor performance status is a predictor of 
shorter survival time (168, 169) and associations between poor physical performance status 
and severe depressive symptoms have also been reported (170, 171). Performance status is 
also a predictor of symptom burden (198) and functional capacity of the patients (199). 
Performance status was reported in 65% of the studies in paper I, and nine of these studies 
used pre-defined cut-off scores for performance status as an inclusion criterion. In paper II, 
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low performance status (KPS scores from 0 to 40) indicated a significant likelihood to receive 
antidepressants in the binary logistic regression with odds ratio of 1.91 and confidence 
interval from 1.05 to 3.46; however it was not significant in multivariate regression analysis. 
This can be explained by the fact that co-morbidity was kept in the multivariate model which 
probably shares variance with Karnofsky Performance Status scores. In general, depression 
disorder is accompanied by poor performance status and the use of antidepressants might 
have improved the patients’ performance. 
 
Information about cognitive function was reported in 23 (38%) of the studies included in 
paper I. Adequate cognitive function was an inclusion criterion among 21 of these 23. 
Cognitive function might be considered as a potential bias because some patients may have 
affective symptoms at the beginning of the development of dementia. In paper II, cognitive 
function was not a specific exclusion criterion other than obvious cognitive impairment as 
judged by those who were study personnel. The mean cognitive function as measured by 
MMSE in the complete sample was 28 and 88 patients had MMSE score below 24 indicating 
impaired cognitive function (158). Even if a large amount of date was collected by patients’ 
self-report requiring adequate cognitive function, this probably does not influence the 
results on a group level in such a large sample. In contrast, in paper III, cognitive function 
might have caused a considerable bias. Cognitive function was reported by attending 
physicians on a rating scale from 1 (conscious) to 5 (unconscious). The physicians might have 
interpreted the patient’s affective withdrawal during a normal dying process as impaired 
cognitive function and/or depressive symptoms. However, patients with scores of 4 and 5 
were excluded from the analyses. 
 
Confusion is common in cancer patients in the last weeks or days if life, usually being part of 
the disorder delirium (81, 200, 201). The prevalence rate is about 50% and represents the 
sign of impeding death in cancer patients (202). It is characterised by disorientation with 
regard to time, place and person and is often accompanied by reduced attention (i.e. 
reduced ability to direct, focus, sustain, and shift attention) and awareness (i.e. reduced 
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orientation to the environment). The prevalence of confusion in paper III was 54%, and 
confusion was significantly associated with the presence of mild/moderate depressive 
symptoms according to physicians rating (p=0.025). This high prevalence of confusion in the 
last 24 hours of life could be explained as a normal part of the dying process or maybe also 
by use of different medications. Furthermore, 73% of the patients in paper III were 
experiencing severe/very severe fatigue in the last 24 hours of life. Attending physicians may 
have interpreted fatigue as part of the dying process or as a depressive symptom.  
 
5.1.1.3 Pain and depression/depressive symptoms 
Illness related symptoms either from the cancer disease or comorbidities, e.g. pain or fatigue 
(16, 17), are likely to be associated with depression (203). However, this might be a matter 
of the chicken and the egg paradox (130, 131). For optimal management of depression, the 
assessment and reporting of subjective symptoms and about their treatment is also 
important. However, in paper I only 22% of the included studies provided information about 
treatment with, for example, opioids. In paper II, patients who were receiving pain 
medication were 2.6 times more likely to use antidepressants, compared with those who did 
not. The study design did not permit to study this relationship further. In paper III, 79% of 
the patients were experiencing any degree of pain in the last 24 hours of life as reported by 
attending physicians. This relatively high percentage is stressing the importance of 
assessment and treatment of symptoms in advanced cancer patients. In the same study, 
association between pain and depressive symptoms was observed in the univariate analysis. 
However, unexpectedly, no such association was found in the logistic regression analysis. 
This could be explained by the fact that pain specialist or palliative care consultants were 
more likely to be involved in the care of the patients with severe/very severe depressive 
symptoms (p=0.023) and therefore probably paying more attention to symptom burden. 
 
55 
 
5.1.1.4 Depression-specific information 
Paper I revealed that in studies addressing depression, clinical core variables related to 
depression were rarely reported (Figure 3). According to the European Clinical Guidelines for 
the Management of Depression in Palliative Care (103) it is important to assess depression-
related variables such as use of antidepressants, psychiatric history, and duration of 
depressive episode when diagnosing depression. Information about medication is 
considered as integral part of the medical history. Family history of depressive disorders as 
well as duration of present or previous depressive episodes increase the risk of developing 
new depressive episodes (139, 140) and thus important to assess. Furthermore, we think 
that assessment and reporting of variables such as history of alcohol and drug abuse may be 
interesting as different studies have shown these variables to be a risk factors for developing 
depression in patients with advanced cancer (141, 204) and in general population (205). 
Assessment and reporting of those important variables are needed to have complete 
description of the patient samples with depressive symptoms as well as for clinical practice. 
 
One of the limitations of the present thesis is that some of the variables identified in paper I 
(e.g. previous depressive episode, psychiatric history) were not available for further 
investigation in paper II and III.  
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Figure 3. Reporting of depression-specific clinical information in included 59 studies from 
paper I 
 
 
5.1.2 Prevalence of depression and depressive symptoms 
The prevalence rates of depression and depressive symptoms in the included publications of 
paper I varied between 2% and 56% which confirmed findings from previous studies (87, 
206). A systematic literature review by Hotopf et al. in advanced cancer patients reported 
the median prevalence of ‘definite depression’ of 29% by using the HADS, while by using a 
psychiatric interview the median prevalence of depression was 15% (87). This is similar to 
the finding from paper II, where the prevalence of depression (major depressive disorder) as 
measured by PHQ-9 questionnaire was 12%. A study observing cancer patients in primary 
care found that depressive symptoms were reported in 14% of the patients by using a 
numerical rating scale from 1 to 5 which is comparable with the findings from paper III, 
where 17% of the patients were observed as having depressive symptoms (207).  
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5.1.3 Classification and assessment of depression and depressive symptoms 
During the last decade, important international initiatives have been taken to improve 
assessment and classification of common symptoms and conditions including depression in 
advanced cancer patients (103, 146, 155). Despite these efforts, the majority of the 
reviewed publications in paper I did not apply validated diagnostic systems for diagnosing 
depression (75%) and several different assessment tools were used. This is in concordance 
with results from the systematic literature review by Wasteson et al. regarding studies in 
advanced cancer patients with depression (92).Only 23% of the studies, all published before 
2007, used a formal classification system for diagnosing depression and it was demonstrated 
that more than 100 different assessment methods were used (92). This thesis (paper I) 
showed that the unsystematic use of assessment methods for diagnosing depression 
continues as this percent reached 25. 
 
Classification of depression in patients with advanced cancer is based on criteria of the DSM 
(81) or the ICD (82) diagnostic systems. In paper II, two different inclusive approaches to 
calculate depression by using the PHQ-9 questionnaire were applied: 1. an inclusive DSM-
based algorithm for diagnosing depression, and 2. an established threshold level by the 
summary scores from the PHQ-9. In contrast to these two, an exclusive approach of the 
score calculation has recently been advocated by the European Palliative Care Research 
Collaborative guidelines (103) and some researchers (166, 208, 209) suggesting not to 
include somatic symptoms which are likely to be due to cancer disease. However, the choice 
of using the inclusive approach by our research group was based on rather having false-
positive depression cases then false-negative. In paper III, a diagnosis of depression was not 
applied, but depressive and other symptoms were rated by observers. The questionnaire 
was including the rating scale from 1 to 5 for recording depressive and other symptoms by 
attending physicians, where 1 represented no symptoms and 5 represented very severe 
symptoms. 
 
The difficulties of diagnosing depression and identifying depressive symptoms in advanced 
cancer patients could be explained by for example unsystematic assessment of symptoms 
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(210), lack of communication skills (211), and insufficient training of healthcare providers to 
recognise depressive symptoms in general as well as at the end of life (212). A study 
conducted in a hospital setting showed that only 50% of general practitioners identified 
patients with depressive symptoms (213). Another study showed that about 40% of cancer 
patients reported to be asked about psychological issues during a consultation at oncology 
outpatient clinic (214). Thus, many of the oncologists do not systematically ask about these 
important issues and prefer to rely on patients mentioning symptoms first (215). Evans at al. 
found in a retrospective study that general practitioners from four European countries had 
end-of-life discussions on ten different topics with less than half of patients; however in the 
Netherlands the discussion was most prevalent for all topics (211). Specialized training for 
palliative care professional careers in depression is recommended in order to improve their 
depression-related knowledge, detection skills, and self-efficacy (212). In addition, study 
design and whether depression was a primary study outcome may also play a role. 
 
The PHQ-9 questionnaire (110) was recently added to a list of tools suggested by the DSM-5 
classification system (section III in the DSM-5) to be used for further clinical evaluation and 
research as potentially useful both to make a diagnosis of depression and to enhance clinical 
decision-making (216, 217). This questionnaire has been validated in a palliative care 
population (166). The suggested list by the DSM-5 is also including other tools such as 
PROMIS (60) - Depression questionnaire (218). However, these were designed for different 
populations (e.g. children) and different psychiatric disorders.  
 
The categorical and dimensional concept of depression as a diagnosis and as depressive 
symptoms is considered valuable both in clinical practice and in research (103). The 
distinction may guide treatment decisions as depression and depressive symptoms in most 
cases should be managed differently in clinical practice. In research it is recommended to be 
more clear about which of the two concepts that are in focus when defining the patient 
population, assessment methods, the outcome and potential interventions.  
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5.1.4 Treatment of depression 
In paper II we found that the prevalence of antidepressant use was 14%. The study was 
international including 17 centres from eight different countries. This prevalence rate of 
antidepressant use is comparable with the study by Ashbury et al. (194), showing that 16% 
of the community care cancer patients were receiving antidepressants. Another study by 
Farriols et al. (219) conducted in Spanish advanced cancer patients examined the changes in 
the prescription of psychotropic drugs from 2002 to 2009. Prevalence of antidepressant 
prescription increased significantly from 18% to 27%. A recent population based nationwide 
study conducted by Brelin et al. in 2013 (154) showed that the one year point prevalence of 
antidepressant prescriptions in Norwegian cancer patients was 22% during their last year of 
life. This study is in line with several other studies also showing that antidepressants are 
often prescribed close the death (151, 153, 154, 220). As antidepressants usually needs 
three to four weeks to achieve a therapeutic effect, patients who receive their first 
prescription a few weeks before death most probably will not benefit from such a treatment 
(220). Reasons for why antidepressants were prescribed so late might be due to higher 
prevalence of depressive symptoms at the end of life or that the dying process could be 
interpreted by health care providers as depressive symptoms. In cases where 
antidepressants are not prescribed, it might be due to physicians considering depression and 
depressive symptoms as a normal part of the dying process (221). In general, there is still a 
lack of information on which clinical information is guiding physicians in deciding on 
prescribing antidepressant medication or not. 
 
Antidepressant medication can be prescribed for different medical conditions and symptoms 
others than depression such as anxiety or pain. In paper II, health care providers were asked 
directly if the indication for using antidepressants was other than as adjuvant pain 
medication. Such information is usually lacking in other studies (152, 194, 219). 
Furthermore, many studies lack information on depression diagnosis and report only 
prevalence rates of antidepressant use (154, 186, 194, 219). A recent retrospective 
population-based study from the Netherlands reported only prescription patterns of 
psychotropic drugs (186). 
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Studies show that many patients are prescribed antidepressants close to death (153, 154). 
Reasons for this are not well known. One hypothesis could be that physicians may misjudge 
the dying process as depression. However, the study design in paper II did not allow us to 
further explore this as information on when antidepressants were prescribed, and why, was 
lacking. In paper III, use of antidepressants was not recorded. 
 
5.1.5 Palliative care 
Paper I revealed that different terminology was used to describe the stage of disease of the 
studied patients. These terms included ‘advanced’ in 44% of the studies, ‘palliative’ in 10%, 
‘metastatic’ in 8%, ‘terminally ill’ in 10%, and ‘end-of-life’ in 3%. Some of the studies 
described the patient sample using several of the above mentioned terms which made the 
interpretation of the sample difficult. This finding may point to the different existing views 
on what palliative care is and on the until 2014 lack of an international consensus on how to 
describe a palliative care population (52). Some researchers and clinicians are still 
considering palliative care only as end-of-life care, only in the last few weeks of life (34), 
while many are applying the WHO’s latest definition of palliative care as an approach 
“applicable early in the course of illness” (27). In 2014, the EAPC Basic Dataset was 
published, representing an important step to standardize the description of the populations 
studied in cancer palliative care research (55). 
 
In paper III, cancer patients in general have higher symptom intensity in the last 24 hours of 
life. This finding points to the necessity to increase the understanding of the need for 
systematic assessment of different symptoms during the trajectory of cancer disease. Based 
on the new definition of palliative care (27) early integration of palliative care in the 
management of cancer patients is recommended (222). This point has also been advocated 
in recent years by other researchers (223, 224). Studies have shown improvement in 
symptom management and QOL (222, 225-228).This is probably due to a more standardized 
and systematic approach to symptom assessment in clinical care, thereby increasing the 
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awareness and attention to symptoms at an earlier stage. For example, in the well-known 
study by Temel et al. non-small cell lung cancer patients who were randomized to standard 
care plus palliative care from diagnosis had significantly fewer depressive symptoms and 
better QOL than those receiving standard care only (222). 
  
62 
 
5.2 Methodological considerations 
Understanding of methodological weaknesses and strengths is important to evaluate 
internal and external validity of studies conducted. Internal validity stands for 
representativeness of the study cohort, while external validity is the extent to which the 
results of a study can be generalized to the other populations (229). In the following, 
methodological weaknesses and strengths of the present PhD thesis will be discussed.  
 
5.2.1 Systematic literature review 
The systematic literature review conducted in the present PhD thesis was conducted 
according to the PRISMA reporting guidelines (172), aiming at improving the quality and 
reporting of systematic literature reviews and meta-analysis. However, some checkpoints 
were still missing. Firstly, the protocol should preferably have been registered in a 
systematic review register such as the PROSPERO which is an international prospective 
register of systematic reviews (230).  
 
Even if four major databases were used for the researches, it is questionable whether all 
relevant publications addressing assessment and classification of depression were identified 
in paper I. Publications were included from studies investigating advanced cancer patients 
having depression as an explicitly defined primary endpoint. As the study aimed to only 
focus on studies investigating advanced cancer patients with depression, it was decided to 
limit the inclusion criteria somewhat as compared to the study by Wasteson et al. (92) where 
studies were included if they assessed depression and depressive symptoms with any formal 
or informal tools. It was hypothesized that the description of the patient samples and the 
assessment of depression would be as optimal as possible in a clearly defined population. To 
also include publications investigating cancer patients through the disease trajectory and/or 
cover not only depression as a diagnosis, but also depressive symptoms, might have given 
other results. A predefined checklist was applied for data extraction; by using this 
information from the publications might not have been recorded. However, the list included 
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32 variables and was based upon best available evidence, expert opinions and the EAPC 
Basic dataset (55). 
 
The search only included papers published in English language. Thus, exclusion of studies in 
other languages might have resulted in missed publications of interest. The choice of the 
English language publication was based on the language skills of our research group. Also, 
hand searches of the relevant literature were not conducted which could have identified 
additional relevant publications. Quality rating of the included studies was beyond the scope 
of this systematic literature review since it was a descriptive study of sample descriptors and 
assessment methods used for depression.  
 
5.2.2 Cross-sectional studies 
Paper II used a cross-sectional study design. Cross-sectional studies in general are 
descriptive, collecting data from the population of interest at one specific time point. The 
design is often described as taking a “snapshot” of a group of individuals. Large number of 
participants can be included in such studies relatively quickly without drop-outs being 
strength for the statistical analysis and the generalizability. Data from cross-sectional studies 
may improve understanding of the prevalence of various treatments and conditions, factors 
associated with the outcomes, and may provide valuable information regarding hypotheses 
related to biological and clinical markers. However, a cross-sectional study design has certain 
limitations: First, the exposure and outcomes are assessed simultaneously for each subject 
giving no evidence of a temporal relationship between them (231).Second, a cross-sectional 
design is prohibitive of explaining causality, even if there is an association between variables. 
Consequently, with this design it is not possible to evaluate changes that develop in the 
outcome. The measured association in a cross-sectional study is between exposure and 
having the outcome as opposed to exposure and developing the outcome.  
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Specifically, in paper II, there is a lack of information about indications for antidepressant 
use, information that could have been recorded applying a prospective study design. This 
could have been helpful to understand why antidepressant medication was initially 
prescribed, be it depressive disorders, a high intensity of depressive symptoms or other 
symptoms or conditions such as anxiety, hot flashes, nausea or fatigue. The actual question 
on use of antidepressants, “other than as adjuvant for pain”, does not completely ascertain 
that the antidepressants were used only for depression or depressive symptoms. 
 
Furthermore, the study design provides no information about the initiation and length of 
antidepressant use. Information on when antidepressants were prescribed, for how long 
patients had used these might have provided clinically relevant information. If we assume 
that the antidepressant medication was prescribed for treating depression (e.g. MDD) in 
patients with advanced cancer, it could potentially be that the treatment was successful, by 
yielding a PHQ-9 score below the threshold of a depression diagnosis. However, one has to 
be careful with assumptions like this, even if 75% of the patients using antidepressants did 
not fulfil the diagnostic criteria for depression, due to the methodological considerations 
above (Table 12). Subgroup analyses to compare characteristics of patients with or without 
depression who received antidepressants were not performed as the groups were too small 
to perform statistically sound analyses.  
 
Table 12. The use of antidepressants in patients with and without depression (Major 
Depressive Disorder), paper II 
 Antidepressants Total 
 Yes (n=141) (10)* No (n=907) (71)* 967  
Depression 33 (25%) 99 (12%) 132 (12%) 
No depression 98 (75%) 737 (88%) 835 (88%) 
*Number of missing items on Patient Health Questionnaire - 9. 
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Another limitation of the study applied for analyses in paper II, is the convenience sample. 
The sample might not be fully representative of an advanced cancer population even if this 
was a study inclusion criterion. We lack information about patients who were either not 
informed about the study or who declined participation. Patients who were not informed 
about the study may have had poor conditions and therefore health care providers may 
have acted as gatekeepers for those patients. According to ethical regulations in some of the 
countries it was not allowed to register any data on those who were regarded either 
ineligible or denied participation in this study. Therefore, specific analyses for non-response 
were not performed. Patients, who declined to take part in the study, might have been more 
severely depressed and/or had higher symptom distress and therefore, might have received 
antidepressants. Those limitations may have contributed to a ‘healthier’ sample of advanced 
cancer patients. Included patients were relatively young (74% were under age of 70 years 
with the mean age of 62.5) with mean performance status of 70. One explanation for this 
could be that study used hand-held computers for symptom assessment where the eldest 
either denied taking part in the study since they do not use computers on the daily bases 
and might be doubtful about modern technology, or that they were not approached by 
research nurses.  
 
This study has several strengths as well. The sample size was large including more than 1000 
patients with advanced cancer, and the compliance rate was high with 95% of the patients 
completing all assessments. The primary aim of the CSA study was to find out if symptom 
assessment in patients with advanced cancer is feasible by using hand-held computers. Our 
study demonstrated positive results and measured prevalence of depression. The PHQ-9 
questionnaire which was used in the study is based on DSM-5 diagnostic criteria and has 
been validated in cancer patients. Paper II gives useful information on antidepressant use in 
advanced cancer patients from eight different countries including Europe, Australia and 
Canada. 
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Do the models explain the variation in AD use? 
Regression analysis was chosen as the most appropriate method of analysis in paper II to 
study which variables were associated with the use of antidepressants. The explained 
variance (R2) was low (11.8%), indicating the weak association between independent and 
dependent variables and the chance of using antidepressants. This low variance indicates 
that several other aspects than the ones investigated might have contributed to the use of 
antidepressants. Information regarding for example the presence of previous depressive 
episodes and the treatment given, duration of the present depressive episode, and 
indication and duration of the present antidepressant treatment might have improved the 
model performance.  
 
5.2.3 Retrospective studies 
Retrospective studies are using previously collected or historical data for the information of 
interest. This study design is relatively cheap and easy for researchers to conduct. It allows 
retrieving information using chart reviews, past records or medical files. Although 
retrospective study design is usually discouraged when a prospective study design is feasible, 
a retrospective study can serve a useful purpose. It allows collecting the data which is 
difficult to obtain by a prospective study design e.g. collecting information on patients in 
their last days of life and of course data from decedents. A retrospective study design allows 
for: easy identification of relevant patient samples, to study all patients who came to the 
end of life, and facilitate the development of measures that can be used to monitor end-of-
life care across different geographical areas, health care providers or time period (e.g. 
measuring quality of end of life care) (232). 
 
Paper III was a retrospective study. The time between sending the questionnaire to the 
physicians and actual death was up to two months. This time lag might have caused a recall 
error on the part of the physicians, as it may be difficult to score symptoms retrospectively. 
Ten percent of the questionnaires had missing data on depressive symptoms, which 
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probably illustrates some difficulties physicians might have had in assessing depression or 
recalling this information. In 60% of the cases general practitioner was the physician who 
signed the death certificates. This might indicate that the observer knew their patients and 
families well limiting the recall difficulties.  
 
Patient ratings are considered as the ‘gold standard’ for assessing and self-reporting 
subjective symptoms in cancer patients. However, studies on health care providers and 
significant others suggest that proxy rating is a feasible solution in patients at the end of life. 
The agreement between self-report and proxy reports vary greatly in the last days of life 
(233) and proxy assessment may substitute patient report when patients are unable to 
provide self-assessment due to severe symptom distress and rapid health deterioration 
(234), confusion (235), and/or communication difficulties (234). The proxies’ judgments 
about symptoms are found to be reasonably adequate, and the benefits of the proxy rating 
outweigh limitations when studying groups that would otherwise have been excluded from 
the studies (236-238). However, the use of proxies has limitations. Results from different 
studies in cancer patients demonstrate that health care providers often under-estimate 
symptom severity or frequency (62-66). This is more obvious when reporting psychological 
symptoms (63, 64, 67). In paper III attending physicians were used as proxies for reporting 
symptoms in cancer patients in the last 24 hours of patients’ life. 
 
In addition, no standardized measure with not validated cut-off scores was used for 
reporting different symptoms including depression. In paper III no question was asked to 
physicians if they assessed depression with any formal tools before death or if they were 
specially trained for identification of depression or depressive symptoms at the end of life. 
There is a lack of information on the prior use of medication by the sample such as 
antidepressants, other psychotropic drugs, opioids which may lead to fatigue, confusion or 
development of other distressing symptoms at the end of life. Detailed registration of 
interventions for depressive symptoms, duration of receiving antidepressant medication, 
information on when depression was first identified, and duration of depressive symptoms, 
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would have given important information about depression and treatment outcomes. 
However, this was beyond the scope of this study as it described existing end-of-life practice 
in the Netherlands. 
 
This study has several strength. The sample was stratified and then randomly selected which 
allowed the generalizability of the findings in the Netherlands. Sample size was also quite 
large providing us with adequate number of cancer patients (n=1363) with information on 
depressive symptoms increasing reliability of the study. Thus, paper III still adds valuable 
information to be used for improving symptom management in cancer patients at the end of 
life.  
  
69 
 
6. CONCLUSIONS 
Depression and depressive symptoms are burdensome and commonly experienced by 
patients with advanced cancer. This thesis has contributed with three studies to the 
knowledge about depression and depressive symptoms in advanced cancer patients 
covering prevalence rates of depression and depressive symptoms as well as of use of 
antidepressant medication, and assessment and classification of depression and depressive 
symptoms: one systematic literature review, one study of empirical data from a cross-
sectional international multicentre study, and one national retrospective death certificate 
study from the Netherlands. 
The following conclusions can be drawn answering the research questions of the thesis: 
x Age, gender, and cancer diagnosis were the most frequently reported background 
variables in studies of depression among patients with advanced cancer. Several socio-
demographic and medical variables were inconsistently reported. 
x Depression-related variables such as psychiatric history, duration of present depressive 
episode and treatment with antidepressants and/or psychotherapy were seldom 
reported in the studies on depression in patients with advanced cancer. 
x The assessments methods varied considerably in the studies on depression in patients 
with advanced cancer. 
o Structured and unstructured clinical interviews were used in 15 (25%) of the 
studies while the rest 44 (75%) used depression-specific self-reported 
questionnaires.  
o 25% of the studies classified depression according to diagnostic system such as 
the DSM- and ICD-10 criteria.  
The lack of consistent reporting of clinically relevant variables and the variability of 
assessment methods hamper the comparison of results across studies of depression. 
These findings can help in establishing a consensus on how to report relevant 
explanatory variables and measure depression in future studies. 
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x The prevalence of antidepressant use was 14% in the international sample of patients 
with advanced cancer.  
x Multiple co-morbidities, medication for pain, younger age and female gender were 
associated with the use of antidepressants.  
x The variables associated with the use of antidepressants partially differ from the 
variables shown to be associated with depression in patients with advanced cancer.  
 
x Overall, 37.6% of dying patients experienced depressive symptoms as evaluated by their 
physicians in their last 24 hours of life;  
o 31.8% had mild/moderate and 5.8% had severe/very severe depressive 
symptoms respectively. 
x Odds for having mild/moderate depressive symptoms were higher in younger patients as 
compared to the old. 
x Fatigue, confusion and anxiety were associated with the presence of depressive 
symptoms. 
x Physicians working in the nursing homes in the Netherlands, pain specialists/palliative 
care consultants and psychiatrists/psychologists were more likely to be involved in the 
care of the patients with severe depressive symptoms.  
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7. FUTURE PERSPECTIVES 
The findings presented in this thesis are only initial steps to illuminate the complexity of 
depression in patients with advanced cancer. Further systematic efforts are needed both in 
research and in clinical practice to better classify, assess and treat depression in patients 
with advanced cancer to improve patients’ QOL. More focus on implementation of existing 
guidelines and research results into clinical practice is needed as well.  
 
Guidelines exist in most disciplines in medicine, including guidelines for depression in 
chronic health problems and in palliative care (103, 146). Guidelines should be evidence 
based, feasible, frequently used, dynamic and updated regularly (239). Implementation of 
guidelines into clinical practice and change of practice in general is challenging (240, 241). 
Different barriers and facilitators have been identified in the last years. Examples are related 
to management, education, and clinical utility (240). Results from paper I with regard to 
inconsistent reporting of depression-specific variables in clinical trials make it relevant to 
think that if research is to influence clinical practice, the assessments performed in research 
should mirror best clinical practice. The external validity of many of present published 
studies on depression in advanced cancer patients might be questionable. 
 
Tools should be tested in large multicentre studies to better understand how the chosen 
variables work and if any modifications are needed. Rigorous descriptions of study 
populations are desirable to increase the generalizability of results from studies on 
depression in patients with advanced cancer. There is a need to obtain consensus on this 
topic. Researchers and clinicians should be more aware of the important distinction between 
depression as a diagnosis and depressive symptoms, and to be able to better identify 
patients in need of treatment in order to improve clinical practice. 
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Multiple symptoms, and especially depressive symptoms, in cancer patients at the end of life 
still call for special attention to improve identification. This could be done by including 
specialists in the management of depression and/or depressive symptoms in cancer patients 
as well as focusing on education of specialists and general practitioners. Furthermore, there 
is a need for more knowledge regarding the dying process. To better understand e.g. the 
pathophysiology might increase the clinical understanding and assessment of common 
symptoms at the end of life.  
 
Early identification as well as timely offer of interventions including palliative care might 
improve overall symptom control and QOL. For studies addressing depression or depressive 
symptoms in patients with advanced cancer depression-related variables such as duration of 
present depressive episode, psychiatric history, and ongoing treatment for depression 
should be assessed and reported. Stakeholders, such as editors of medical journals, the 
EAPC, other palliative care organizations, the EAPC Research Network, and the European 
Palliative Care research Centre (PRC) may bring this work forward by agreeing that a 
standard set of core variables characterising the study population should be mandatory 
when publishing study results. The use of the EAPC basic dataset (55) in all clinical studies 
addressing advanced cancer patients may be one important step towards standardization 
and improved quality of research and clinical practice. 
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Abstract
Context. Prevalence rates of depression in patients with advanced cancer vary
considerably. This may be because of heterogeneous samples and use of different
assessment methods. Adequate sample descriptions and consistent use of
measures are needed to be able to generalize research ﬁndings and apply them to
clinical practice.
Objectives. Our objective was twofold: First, to investigate which clinically
important variables were used to describe the samples in studies of depression in
patients with advanced cancer; and second, to examine the methods used for
assessing and classifying depression in these studies.
Methods. PubMed, PsycINFO, Embase, and CINAHL were searched combining
search term groups representing ‘‘depression,’’ ‘‘palliative care,’’ and ‘‘advanced
cancer’’ covering 2007e2011. Titles and abstracts were screened, and relevant full-
text articles were evaluated independently by two authors. Information on 32
predeﬁned variables on cancer disease, treatment, sociodemographics,
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depression-related factors, and assessment methods was extracted from the
articles.
Results. After removing duplicates, 916 citations were screened of which 59
articles were retained. Age, gender, and stage of the cancer disease were the most
frequently reported variables. Depression-related variables were rarely reported,
for example, antidepressant use (17%) and previous depressive episodes (12%).
Only 25% of the studies assessed and classiﬁed depression according to a validated
diagnostic system.
Conclusion. Current practice for describing sample characteristics and assessing
depression varies greatly between studies. A more standardized practice is
recommended to enhance the generalizability and utility of ﬁndings.
Stakeholders are encouraged to work toward a common standard for sample
descriptions. J Pain Symptom Manage 2014;48:678e698.  2014 American
Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
Key Words
Advanced cancer, palliative care, depression, generalizability, assessment
Introduction
Depression is probably the most studied psy-
chiatric disorder in advanced cancer patients,1
with reported prevalence rates ranging from
3% to 58%.2,3 The great variability in preva-
lence rate estimates reﬂects in part the hetero-
geneity of the populations studied and in part
the lack of agreed-on standards for deﬁning
and assessing depression in this patient group.
Thus, clear descriptions of the study sample
and of the assessment methods are necessary
to judge the generalizability of study ﬁndings
and their relevance for clinical practice.4
Common symptoms of advanced cancer dis-
ease, such as fatigue, lack of appetite, and sleep
problems, are also used as diagnostic criteria for
depression (e.g., Diagnostic and Statistical Manual
ofMental Disorders, FifthEdition [DSM-V]; Interna-
tional Statistical Classiﬁcation of Diseases and Related
Health Problems, Tenth Revision [ICD-10]).5,6 De-
pending on which symptoms are included in
the different depression assessment methods,
the extent of the cancer disease may to varying
degrees inﬂate the number of false-positive
depression cases and consequently threaten the
validity of the depression assessment and inﬂu-
enceprevalence rateestimates.7e12Furthermore,
a systematic literature review published in 2009,
covering the period from 1966 to 2007, demon-
strated that 106 different assessment tools for
depression were applied in studies in palliative
cancer careand that a validateddiagnostic system
was used only in a minority of the studies.13 If
these diverse assessment practices still dominate,
is not known. However, to reduce the problem of
the great variation in sample descriptions and
depression assessment methods as presented in
the literature, theEuropeanUnion-fundedEuro-
pean Palliative Care Research Collaborative
(www.epcrc.org) worked toward developing a
standardizedassessment andclassiﬁcation system
for common symptoms in palliative care cancer
patients.14 This work has been continued within
the European Palliative Care Research Centre
(www.ntnu.edu/prc), an international research
collaborative with the overall aim to improve
symptom management and research quality in
palliative care.
Adding to the problem of a valid assessment
of depression, is the heterogeneous nature of
advanced cancer populations with regard to
age, diagnosis, extent of the cancer disease, sur-
vival, symptom burden, comorbidity, physical
functioning, and need for treatment and
follow-up.15e17 A precise characterization of the
study sample is needed to be able to compare re-
sults across studies and transfer researchﬁndings
to clinical practice.4,18,19 An international expert
group recently emphasized poor and unsystem-
atic reportingof sample characteristics in clinical
studies in palliative care as an important barrier
for conducting high-quality research.20 Stan-
dardized descriptions of patient samples have
been advocated for clinical studies in general.
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The Consolidated Standards of Reporting Trials
Statement was developed 20 years ago and in-
cludes a 25-item checklist and a participant
ﬂow diagram to guide the reporting from ran-
domized controlled trials (RCTs), also including
speciﬁcations onhow to describe the population
studied.21 Similarly, the Strengthening the Re-
porting of Observational Studies in Epidemi-
ology statement recommends a checklist of 22
items, including sample characteristics, for re-
porting studies in epidemiology.22 For clinical
studies in palliative care, Currow et al.19,23 have
proposed a similar checklist of core variables to
describe populations and service characteristics,
also applicable for advanced cancer populations
because these terms overlap. The list includes in-
formation related to ﬁve domains: ‘‘individual
participant’s demographics,’’ ‘‘caregiver,’’ ‘‘ser-
vice,’’ ‘‘health and social policy,’’ and ‘‘research.’’
Demographics cover age, gender, socioeco-
nomic status, ethnicity, life-limiting illness, per-
formance status, and days from referral until
death.23 However, despite these statements and
initiatives, a recent literature review investigating
the description of palliative care cancer patient
samples included in RCTs concluded that very
few demographic or disease-related variables
were consistently registered and reported.24
Previous research has identiﬁed several risk
factors for development of depression in can-
cer patients:25 female gender,26 poor perfor-
mance status,27 and certain cancer diagnoses
such as pancreatic,28 lung,29,30 and breast can-
cer.31 Furthermore, a prior psychiatric history,
previous depressive episodes, and alcohol
dependence are known risk factors for devel-
oping depression during the cancer disease
trajectory.32,33 In addition to these risk factors,
the duration of depressive symptoms, their
functional consequences, and ongoing treat-
ment in terms of drugs and/or psychotherapy
are relevant variables to include in a report on
depression in advanced cancer.32,34e36
To the best of our knowledge, no studies
have systematically examined the extent of re-
porting relevant sample characteristics in
studies on depression in advanced cancer.
Thus, the overall aim of the present study is
to identify candidate variables to include
when reporting clinical studies of depression
in advanced cancer patients as well as informa-
tion on how depression is assessed and classi-
ﬁed. The following research questions were
addressed in the present systematic literature
review:
 How were patient samples described in re-
ports on clinical studies of depression in
advanced cancer?
 How was depression assessed and classi-
ﬁed in these studies?
Methods
The databases PubMed, CINAHL (through
EBSCOhost), PsycINFO, and Embase (through
OvidSP) were searched for relevant studies.
The search strings were designed for each data-
base using both free text and controlled vocabu-
lary (e.g., MeSH, CINAHL Headings, APA
Thesaurus, EMtree) and consisted of combina-
tions of terms representing ‘‘depression,’’ ‘‘palli-
ative care,’’ and ‘‘advanced cancer’’ (Appendix I;
available at jpsmjournal.com). The searches
covered the years 2007e2011with the last search
date being January 3, 2012. Search details and
the speciﬁc search strings for all bibliographical
databases will be provided on request by the cor-
responding author.
Titles, abstracts, and keywords of the 916 iden-
tiﬁed citations were independently screened by
two authors (E. J. and A. K. K. or M. J. H. and
D. F. H. or K. R. S. and E. T. L.) to judge their po-
tential relevance. The following inclusion
criteria were applied: clinical study with adult
advanced cancer patients (18 years and older)
and primary study outcome including the term
depressionordepressive disorder. The exclusion
criteria were non-English publications, reviews,
commentaries, case reports, publications ad-
dressing tool development (e.g., validation
studies), and studies with noncancer patients
included in the sample.
The term ‘‘advanced cancer patients’’ was
deﬁned to include patient samples described
with the following terminology: ‘‘palliative,’’ ‘‘met-
astatic,’’ ‘‘terminally ill,’’ ‘‘end-of-life,’’ and/or
‘‘not curable.’’
References deemed eligible for inclusion in
the screening process were then independently
examined in full text by two of the authors. Any
discrepancies between the reviewers’ selections
were discussed to obtain consensus, or a third
author (M. J. H.) was consulted.
A predeﬁned checklist (Appendix II; avail-
able at jpsmjournal.com) was used to extract
data from the identiﬁed full-text articles. The
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list was partially based on the content of the
European Association for Palliative Care
(EAPC) Basic Dataset,37 holding a set of items
recommended for use when reporting results
from studies in palliative cancer care,
including sociodemographic, disease-related,
and patient-reported variables. Speciﬁc vari-
ables of relevance for diagnosing and treating
depression were also included in the list, such
as psychiatric history, previous depressive epi-
sodes, duration of the depressive episode, his-
tory of alcohol and/or drug abuse, and
ongoing treatment for depression (pharmaco-
logical and nonpharmacological). The check-
list also contained information on methods
used for assessment and classiﬁcation (i.e.,
diagnostic system) of depression.13
This was intended as a descriptive study of
sample descriptors and assessment methods,
thus quality rating of the included studies
was beyond the scope of the present report.
Standard statistical procedures were used for
analysis of frequencies. Extracted data were
stored and analyzed in PASW, version 18.0
(SPSS, Inc., Chicago, IL).
Results
Citations and Publications
The search yielded 1669 potentially relevant
citations, of which 753 were duplicates. After
the initial screening of titles, keywords, and
abstracts, 125 (14%)publications of the remain-
ing 916 were retained for full-text examination.
These 125 articles were assessed according to
the predeﬁned inclusion and exclusion criteria,
resulting in the inclusion of 59 publications.
The main reasons for exclusion were publica-
tions not reportingon advanced cancer patients
(13%) and publications not having depression
as a primary outcome (18%) (Fig. 1).
Overview of the Included Studies
All 59 publications (Table 1) addressed
advanced cancer patients having depression as
a study endpoint. Most studies (23 [39%])
were cross sectional, 32% were prospective,
and 12% were RCTs. The sample size ranged
from 23 to 1439 patients. The most common
study locations were general hospital depart-
ments, such as oncology departments (26
[44%]), followed by hospice/palliative care
units (14 [24%]). Outpatient services (36%)
were the most common setting, followed by
inpatient care (30%); 17% of the studies pro-
vided no information about the setting.
Description of the Patient Populations
Table 2 shows results for description of the
patient samples. Age and gender were the
most frequently reported sociodemographic
variables, reported in 93% and 90% of the
studies, respectively. Twenty-nine (49%) studies
reportedmarital status. Informationon religion
was reported in six (10%) and social network
also in six (10%) studies. Performance status
was reported in 38 (65%) studies; nine (15%)
of these studies used performance status as an
inclusion criterion. Information about cogni-
tive function was reported in 23 (38%) studies,
being an inclusion criterion in 21 of these 23.
The stage of the cancer disease was
described as locally advanced, advanced, or
metastatic in 44 (75%) of the studies. Different
terminology to describe the sample for disease
status was applied as follows; ‘‘advanced’’ in 26
Fig. 1. Flowchart presenting the study selection pro-
cess. *The study addresses other symptoms of can-
cer patients and/or cancer treatment.
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(44%) studies, ‘‘palliative’’ in six (10%)
studies, ‘‘metastatic’’ in ﬁve (8%),‘‘terminally
ill’’ in six (10%), ‘‘end-of-life’’ in two studies
(3%), and ‘‘not curable’’ in two (3%).
The following eight of the 17 variables
included in the EAPC Basic Dataset37 were
most often reported: age (93%), gender
(90%), principal cancer diagnosis (97%),
stage of the cancer disease (75%), perfor-
mance status (65%), anticancer treatment
(59%), place of care (91%), and provision of
care (83%). The remaining nine variables of
the EAPC Basic Dataset were less often re-
ported: education (42%), cognitive function
(38%), time since diagnosis (27%), medica-
tion (opioids in 22% and neuroleptics in
5%), living situation (17%), ethnicity (15%),
additional diagnoses (comorbidities) (14%),
site of metastasis (10%), and weight loss
(3%). Expected survival was recorded in eight
(14%) of the studies, and real survival was re-
corded in 15 (25%) of the studies (Table 2).
Depression-Related Variables
Clinical information related to depression
was rarely reported (Table 3). The duration
of the present depressive episode was reported
in two studies (3%).38,39 Information on previ-
ous depressive episodes and psychiatric history
was provided in seven (12%)39e45 and 10
(17%)39,41,45e52 studies, respectively. History
of alcohol and/or drug abuse was reported
in eight (13%)41,48,49,53e57 studies. The use of
antidepressant medication was reported in 10
(17%) studies,27,39,44,52,58e63 whereas different
types of psychotherapies were reported in four
(7%) studies.57,64e66
Assessment and Classiﬁcation of Depression
Depression was classiﬁed according to a
diagnostic system in 15 (25%) studies
(Table 1). The DSM-IV criteria were used in
13 studies,2,38,39,44,46,47,52,58,59,61,62,67,68 the
ICD-10 in one,45 whereas one study53 used
Table 2
Reporting of Patient Characteristics in the 59 Included Studies
Characteristics
No Information
in the Publication,
N (%)
Information in the
Publication, N (%)
Assessed in the Study,
But Not Reported in the
Publication, N (%)
Sociodemographic variables
Agea 1 (2) 55 (93) 3 (5)
Gendera 1 (2) 53 (90) 5 (8)
Ethnicitya 47 (80) 9 (15) 3 (5)
Marital status 28 (48) 29 (49) 2 (3)
Educationa 29 (49) 25 (42) 5 (9)
Religion 52 (88) 6 (10) 1 (2)
Medical information (disease-speciﬁc variables)
Principal diagnosisa 2 (3) 57 (97)
Time since diagnosisa 43 (73) 16 (27)
Stage of cancer diseasea 15 (25) 44 (75)
Metastases 36 (61) 23 (39)
Site of metastasesa 53 (90) 6 (10)
Additional diagnoses (comorbidity)a 51 (86) 8 (14)
Expected survival 51 (86) 8 (14)
Real survival 44 (75) 15 (25)
Weight lossa 57 (97) 2 (3)
Performance statusa 19 (32) 38 (65) 2 (3)
Cognitive functiona 28 (48) 23 (38) 8 (14)
Treatment
Present anticancer treatmenta 24 (41) 35 (59)
Medicationa 43 (73) Opioids 13 (22);
neuroleptics 3 (5)
Caregiver issues
Living situationa 49 (83) 10 (17)
Social network 53 (90) 6 (10)
Setting
Place of carea 5 (9) 54 (91)
Provision of carea 10 (17) 49 (83)
aVariables included in the European Association for Palliative Care Basic Dataset.37
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the revised DSM-III criteria.69 Different assess-
ment methods were applied in these 15
studies: structured clinical interviews were
used in nine,2,38,39,45e47,53,61,67 semistructured
interviews were used in three studies,44,52,68
whereas the remaining three studies58,59,62
gave no information on the assessment
methods used for establishing a diagnosis of
depression.
Forty-four (75%) of the studies did not use a
diagnostic system for classifying depression
(Table 1). However, all but one study70 had
used depression-speciﬁc assessment tools.
Among these, patient-reported tools were most
commonly used: the Hospital Anxiety and
Depression Scale71 was used in 21 (48%)
studies40e43,50,51,55,63e66,72e81 and different ver-
sions of the Beck Depression Inventory82 in 11
(25%),27,48,49,54,56,60,83e87 whereas nine studies
used other depression-speciﬁc question-
naires.57,88e95 Two studies96,97 used the
interviewer-administered Hamilton Depression
Rating Scale.98 In most studies, more than one
assessment method was used.
Discussion
This systematic literature review included 59
full-text articles on depression in patients with
advanced cancer published during the ﬁve-year
period 2007e2011. The description of the pa-
tient samples and how depression was assessed
and classiﬁed varied considerably across studies.
Our ﬁndings conﬁrm that the reporting of
important characteristics of advanced cancer pa-
tient samples is unsystematic. Age, gender, and
cancer diagnosis were the most frequently re-
ported sociodemographicandmedical variables,
conﬁrming the previous ﬁndings by Sigurdar-
dottir et al.24 As a novel ﬁnding, clinically impor-
tant information related to depression, such as
psychiatric history, duration of the present
depressive episode, and treatment (drug treat-
ment with antidepressants and/or psychological
therapy), was rarely reported. In 25% of the
studies, depression was classiﬁed according to a
validated diagnostic system. This result is similar
(23%) to the ﬁnding in an earlier review of
studies published before 2007.13
The prevalence rate estimates of depression
in the included publications varied between
2% and 56%, except for six studies39,58,59,61,62,67
having depression as an inclusion criterion and
thus a prevalence rate of 100%. This variability
conﬁrms previous ﬁndings13,99,100 and under-
lines the need for standardization of how to
characterize patient samples and of how to
assess and classify depression in advanced can-
cer patients. The European Clinical Guidelines
for the Management of Depression in Palliative
Care stress the importance of assessing
depression-related variables such as use of anti-
depressants, psychiatric history, and duration of
thedepressive episodewhendiagnosingdepres-
sion.101 Information regarding medication is a
crucial part of anymedical history, and informa-
tion on previous and ongoing treatment with
antidepressants is part of a complete descrip-
tion of a patient with depressive symptoms.
However, only 11 (17%) of the studies included
in the present work reported information about
treatment with antidepressants. A history of
depressive disorder (e.g., major depressive dis-
order or dysthymia) and long duration of the
depressive episode heighten the risk for devel-
oping new or subsequent depressive epi-
sodes.102,103 Despite this knowledge, data on
these variables were rarely reported in the re-
viewed publications. If research is to inﬂuence
clinical practice, the assessments performed in
research should mirror best clinical practice.
Thus, one might question the external validity
of many of the published studies on depression
in advanced cancer patients.
Table 3
Reporting of Depression-Speciﬁc Clinical Information in the 59 Included Studies
Characteristics
No Information,
N (%)
Information,
N (%)
Assessed in the
Study, But Not Reported
in the Publication, N (%)
Use of antidepressants 49 (83) 10 (17) d
Different types of psychotherapy 55 (93) 4 (7) d
Psychiatric history 40 (68) 10 (17) 9 (15)
Duration of present depressive episode 57 (97) 2 (3) d
Previous depressive episodes 48 (81) 7 (12) 4 (7)
History of alcohol and/or drug abuse 50 (85) 8 (13) 1 (2)
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Classiﬁcationofdepression is basedoncriteria
of diagnostic systems such as DSM-V.5 To diag-
nose adepressivedisorder in anadvanced cancer
patient may be challenging as these patients
commonly experience similar somatic symptoms
from the cancerdisease itself. Itmay beproblem-
atic to decide which of the somatic symptoms
identiﬁed in the DSM-V criteria are attributable
to depression and which are because of cancer
disease.8 Possible confoundingeffects of the can-
cer disease should thus be taken into consider-
ation when investigating depression in patients
with advanced cancer. This can be done by
includingmeasures of disease load, for example,
time to death, performance status, and how the
cancer disease inﬂuences symptoms of depres-
sion, particularly the somatic symptoms.104
Most investigated studies did in fact report in-
formation about the cancer disease (97%) and
its stage (75%).However, despite thewidespread
use of the tumor, node, metastasis classiﬁcation
system in oncology in general,105 it might not
be expected that staging information can be
presented similarly for all different types of
cancer. Anticancer treatment should be taken
into consideration in studies including cancer
patients, especially with advanced disease. How-
ever, information on present anticancer treat-
ment was only reported in 59% of the studies.
The terminology related to describing the sam-
ple as palliative care patients vs. patients with
advanced disease differed across studies. For
example, the term ‘‘palliative’’ was used in 10%
of the studies, whereas ‘‘advanced’’ was used in
44%. This may reﬂect different existing views of
what ‘‘palliative care’’ is. In some settings, pallia-
tive care is viewed as only the last few weeks
before death, whereas others deﬁne palliative
care from the day the patient is beyond cure.
Integration of palliative care into oncology has
in recent years been in focus.106e108
Furthermore, it is important to take into ac-
count information on other symptoms, as
most patients with advanced cancer report mul-
tiple coexisting distressing symptoms72 that
have been shown to be interdependent.109
Even if the direction of causality of these rela-
tionships is unclear,110 the presence of symp-
toms common in advanced cancer patients,
such as uncontrolled pain or cachexia,111,112
may inﬂuence the presence of depression. As
such, information about pain treatment is also
important to report. However, only 22% of
the studies provided information about treat-
ment with, for example, opioids.
Ethnicity may be of clinical relevance, for
example, in a patient with depression who
has moved from one country to another, and
it is well known that depressive feelings and
symptoms are reported in different ways in
different cultures. However, there is no stan-
dardized manner in how to address this, as
far as we know, other than acknowledging cul-
ture as a relevant factor.
Wasteson et al.13 demonstrated that depres-
sion was frequently not classiﬁed according to a
diagnostic system and that more than 100
different assessment methods were used. Thus,
our systematic literature review conﬁrms that
the unsystematic use of assessment methods for
diagnosing depression in advanced cancer pa-
tients continues. Among the included studies,
only 15 used structured or semistructured inter-
views based on an approved classiﬁcation system
for diagnosing depression. A structured clinical
interview is currently the reference standard for
diagnosing depression in clinical practice.113
However, a structured interview is time
consuming and may be difﬁcult to conduct in
frail and fatiguedcancerpatientswithapoorper-
formance status. Several self-reporting screening
tools have been designed to assess depression,
butmost often they assess the intensity of various
depressive symptoms and are insufﬁcient for
diagnostic purposes.
When deciding on which assessment method
to use, a clear understanding of what is to be as-
sessed is paramount: depressive disorder or psy-
chological distress/depressive symptoms. Our
recommendation is that for the assessment of
depressive disorders, a self-report tool based on
the standardized diagnostic criteria of the DSM
should be applied, when a structured clinical
interview cannot be undertaken. The Patient
Health Questionnaire-9 is such a tool,114 which
has been validated in patients with cancer.115 Us-
ing the same tool across depression studies can
facilitate more accurate comparisons.
For the assessment of psychological distress/
depressive symptoms, several more general
assessment tools are available, either in the
form of general symptom assessment tool,
quality-of-life tools, and symptom-speciﬁc tools.
Examples of frequently used tools are the Euro-
pean Organization for Research and Treatment
of Cancer Quality of Life Questionnaire-C30,116
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Functional Assessment of Cancer Therapy
Scale,117 and the Distress Thermometer.118
Among speciﬁc depression tools, the Hospital
Anxiety and Depression Scale for self-report of
both depression and anxiety71 and Beck Depres-
sion Inventory82 are well-known instruments.
Furthermore, the new Patient-Reported Out-
comes Measurement Information System
(PROMIS)-Depression instrument from the
PROMIS119 is currently being developed.120,121
This tool is intended for use by computers and
uses a computer-adaptive testing algorithm as
part of the software, which makes it easier to
tailor the questions to the individual patient.
However, both the methods and tools itself
need to be validated against structured clinical
interviews, in cancer and other patient groups.
A potential limitation in all reviews is whether
all relevant publications are identiﬁed. In this
systematic literature review, we only included
publications from studies investigating advanced
cancer patients and explicitly deﬁning depres-
sion as a primary outcome. This was done
because we hypothesized that the description
of the patient samples and the assessment of
depression would be as optimal as possible in a
clearly deﬁned population. An extension of the
inclusion criteria to cover cancer patients in gen-
eral and/or depressive symptoms in a broader
sense may of course have given other results. A
predeﬁned relatively comprehensive checklist
was used for data extraction; however, it can
never be ruled out that the use of an even more
extensive checklistmay haveprovidedadditional
information. The limitations of the selection
procedure regarding period and language imply
that we might have missed publications of inter-
est. The search covered the ﬁve-year period
2007e2011. This was chosen because an exten-
sive systematic literature review by Wasteson
et al.13 on assessment and classiﬁcation of
depression in palliative care covered the period
until 2007. The search was conﬁned to studies
published in English language according to the
language skills of our research group and
because this is a common procedure for most
reviews. Our selection of the well-known major
databases representing various disciplines, and
the use of recognized search strategy to identify
relevant literature in advanced cancer was
applied,13 make us think that the restriction to
the English language is not a major study limita-
tion. Despite the limitations, we think that the
present review presents valuable new informa-
tion onhowpatients are characterized in clinical
studies having depression as a primary outcome.
Further work toward a consensus on how to
characterize study samples in advanced cancer
patients with depression should in our opinion
include patients’ sociodemographic character-
istics, disease-related information, and infor-
mation on depression-speciﬁc risk factors. In
addition, information on common symptoms
and conditions such as pain and depression
should be reported. Our general recommen-
dation for clinical studies investigating
advanced cancer samples is to include the
EAPC Basic Dataset37 as well as information
about the cancer disease and anticancer treat-
ment. In addition, for depression-speciﬁc
studies, we recommend to assess duration of
the depressive episode, psychiatric history,
and ongoing treatment for depression as a
minimum of depression-related variables.
Stakeholders such as the European Associa-
tion for Palliative Care Research Network
(EAPC RN) in collaboration with core journals
and other relevant bodies could bring this
work forward by agreeing on a common set
of core variables that precisely describe a study
population. Furthermore, editors of medical
journals could be requested to use the agreed
common data set as a checklist.
Conclusions
Our systematic literature review demon-
strates unsystematic and inconsistent reporting
of core sociodemographic and medical sample
characteristics in populations with advanced
cancer and depression. The major ﬁnding
was the lack of reporting of important
depression-related variables in studies investi-
gating depression in advanced cancer patients.
Validated diagnostic tools for depression were
rarely used. Assessment methods for depres-
sion continued to vary greatly. There is an
obvious need for a more stringent character-
ization of study populations to increase the
generalizability of results from studies on
depression in patients with advanced cancer.
We hope our results will inspire journals and
other central stakeholders to produce recom-
mendations for sample descriptions and assess-
ment methods in future studies.
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Appendix I
Search Strategy PubMed
(Depressive disorder[mh] OR Depression[mh] OR depression[tiab] OR depressive[tiab]) AND
(Palliative care[mh] OR palliat* [tiab] OR Terminal care[mh] OR terminal care[tiab] OR end-of-
life care[tiab] OR supportive care[tiab] OR comfort care[tiab] OR Hospices[mh] OR hospice*
[tiab] OR Terminally ill[mh] OR (terminal*[tiab] AND (ill[tiab] OR illness*[tiab])) OR (advanced
[tiab] AND cancer[tiab])) AND cancer[sb] e Limits: Publication Date from 2007.
Appendix II
Extraction Log
Categories Alternatives
Author Name of the ﬁrst author
Year Publication year
Country If the study is multinational please, write ‘‘multinational’’
Journal Name of the journal
Study design 0 ¼ Prospective/longitudinal, 1 ¼ Cross-sectional,
2 ¼ Retrospective, 3 ¼ Intervention, 4 ¼ RCT
Sample size Indicate number at inclusion
Terminology used to describe the sample 0 ¼ No information, 1 ¼ Advanced, 2 ¼ Palliative,
3 ¼ Metastatic, 4 ¼ Terminally ill, 5 ¼ End-of-life,
6 ¼ Not curable/not operable, 7 ¼ Multiple
terminology used
Follow-up Provide time of the follow-up
Study main outcome
Assessment and classiﬁcation of depression
Is depression classiﬁed according to a diagnostic system? 0 ¼ No information, 1 ¼ Yes, 2 ¼ No
If ‘‘yes,’’ which system was used 0 ¼ DSM-IV, 1 ¼ DSM-III, 2 ¼ ICD-10, 4 ¼ Other
If ‘‘other,’’ please specify
Which type of interview was used for diagnosing
depression?
0 ¼ No information, 1 ¼ Structured, 2 ¼ Unstructured
Please provide the name of the interview
Percentage of patients with depression 0 ¼ No information, 1 ¼ Information
Specify percentage of patients
Is depression assessed by using depression-speciﬁc
instruments?
0 ¼ No, 1 ¼ Yes
If ‘‘yes,’’ please, specify
Are QoL instruments used for assessment of depression 0 ¼ No, 1 ¼ Yes
If ‘‘yes,’’ please specify
Depression-related variables
Use of antidepressants 0 ¼ No information, 1 ¼ Information
Different types of psychotherapy 0 ¼ No information, 1 ¼ Information
Duration of present depressive episode 0 ¼ No information, 1 ¼ Information, 2 ¼ Assessed but
not reported
Previous depressive episodes 0 ¼ No information, 1 ¼ Information, 2 ¼ Assessed but
not reported
Psychiatric history 0 ¼ No information, 1 ¼ Information, 2 ¼ Assessed but
not reported
History of alcohol and/or drug abuse 0 ¼ No information, 1 ¼ Information, 2 ¼ Assessed but
not reported
Description of patient samples
Sociodemographic variables
Age/date of birtha 0 ¼ No information, 1 ¼ Information, 2 ¼ Assessed but
not reported
Gendera 0 ¼ No information, 1 ¼ Information, 2 ¼ Assessed but
not reported
(Continued)
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Appendix II
Continued
Categories Alternatives
Ethnicitya 0 ¼ No information, 1 ¼ Information, 2 ¼ Assessed but
not reported
Marital status 0 ¼ No information, 1 ¼ Information, 2 ¼ Assessed but
not reported
Educationa 0 ¼ No information, 1 ¼ Information, 2 ¼ Assessed but
not reported
Religion 0 ¼ No information, 1 ¼ Information, 2 ¼ Assessed but
not reported
Medical information (disease-speciﬁc variables)
Principal diagnosisa 0 ¼ No information, 1 ¼ Information
Time since diagnosesa 0 ¼ No information, 1 ¼ Information
Stage of cancer diseasea 0 ¼ No information, 1 ¼ Described as locally advanced,
advanced, or metastatic/disseminated (information
provided)
Metastases 0 ¼ No information, 1 ¼ Information
Site of metastasesa 0 ¼ No information, 1 ¼ Information
Patients’ additional diagnoses (comorbidities)a 0 ¼ No information, 1 ¼ Information
Expected survival 0 ¼ No information, 1 ¼ Information
Real survival 0 ¼ No information, 1 ¼ Information
Weight lossa 0 ¼ No information, 1 ¼ Information
Performance statusa 0 ¼ No information, 1 ¼ Inclusion criterion, 2 ¼ Speciﬁed,
3 ¼ Both 1 and 2, 4 ¼ Assessed but not reported
Cognitive functiona 0 ¼ No information, 1 ¼ Inclusion criterion, 2 ¼ Speciﬁed,
3 ¼ Both 1 and 2, 4 ¼ Assessed but not reported
Treatment
Present anticancer treatment 0 ¼ No information, 1 ¼ Information
Medication
Opioidsa 0 ¼ No information, 1 ¼ Information
Neurolepticsa 0 ¼ No information, 1 ¼ Information
Caregiver issues
Living situationa (information about caregiver issues
or household/living with, more than marital status)
0 ¼ No information, 1 ¼ Information
Information about social network 0 ¼ No information, 1 ¼ Information
Information about setting
Place of carea 0 ¼ No information, 1 ¼ Home, 2 ¼ Long-term care
facilities, 3 ¼ Hospice/palliative care unit, 4 ¼ Hospital,
general departments including oncology department,
5 ¼ Other, 6 ¼ Two/multiple locations
Provision of carea 0 ¼ No information, 1 ¼ Inpatients, 2 ¼ Outpatients,
3 ¼ Both 1 and 2
Comments
RCT ¼ randomized controlled trial; DSM-IV¼ Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; DSM-III ¼ Diagnostic and Statis-
tical Manual of Mental Disorders, Third Edition; ICD-10 ¼ International Statistical Classiﬁcation of Diseases and Related Health Problems, Tenth Revision;
QoL ¼ quality of life.
aVariables included in the EAPC Basic Dataset.
698 Vol. 48 No. 4 October 2014Janberidze et al.

Paper II

The use of antidepressants in patients with advanced cancer
—results from an international multicentre study
Elene Janberidze1,2*, Marianne Jensen Hjermstad1,3, Cinzia Brunelli1,4, Jon Håvard Loge1,5,6, Hanne Cathrine Lie5,6,
Stein Kaasa1,2 and Anne Kari Knudsen1,2 on behalf of EURO IMPACT
1European Palliative Care Research Centre, Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science
and Technology, Trondheim, Norway
2Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
3Regional Centre for Excellence in Palliative Care, Department of Oncology, Oslo University Hospital, Oslo, Norway
4Palliative Care, Pain Therapy and Rehabilitation Unit, Fondazione IRCCS Istituto Nazionale Tumori Milano, Milano, Italy
5National Resource Centre for Late Effects After Cancer Treatment, Oslo University Hospital, Oslo, Norway
6Department of Behavioural Sciences in Medicine, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway
*Correspondence to: European
Palliative Care Research Centre,
Department of Cancer Research
and Molecular Medicine, Faculty
of Medicine, Norwegian
University of Science and
Technology (NTNU)
Kunnskapssenteret 4.etg., St.
Olavs Hospital, N-7006
Trondheim, Norway. E-mail:
elene.janberidze@ntnu.no
Received: 20 December 2013
Revised: 10 March 2014
Accepted: 14 March 2014
Abstract
Objectives: Depression is common in patients with advanced cancer; however, it is not often recognized
and therefore not treated. The aims of this study were to examine the prevalence of the use of antide-
pressants (ADs) in an international cross-sectional study sample and to identify sociodemographic and
medical variables associated with their use.
Methods: The study was conducted in patients with advanced cancer from 17 centres across eight
countries. Healthcare professionals registered patient and disease-related characteristics. A dichoto-
mous score (no/yes) was used to assess the use of ADs other than as adjuvant for pain. Self-report
questionnaires from patients were used for the assessment of functioning and symptom intensity.
Results: Of 1051 patient records with complete data on ADs, 1048 were included (M:540/F:508,
mean age 62 years, standard deviation [SD] 12). The majority were inpatients, and 85% had meta-
static disease. The prevalence of AD use was 14%. Multivariate logistic regression analyses showed
that younger age (odds ratio [OR] 2.46; conﬁdence interval [CI] 1.32–4.55), female gender (OR
1.59; CI 1.09–2.33), current medication for pain (OR 2.68; CI 1.65–4.33) and presence of three or
more co-morbidities (OR 4.74; CI 2.27–9.91) were associated with AD use for reasons other than pain.
Disease-related variables (diagnoses, stage, Karnofsky Performance Status and survival) were not
associated with the use of ADs.
Conclusions: Female gender, younger age, analgesic use and multiple co-morbidities were associ-
ated with the use of ADs. However, information is still limited on which variables guide physicians
in prescribing AD medication. Further longitudinal studies including details on psychiatric and med-
ication history are needed to improve the identiﬁcation of patients in need of ADs.
Copyright © 2014 John Wiley & Sons, Ltd.
Background
Antidepressant medication is an effective treatment for
different psychiatric disorders as deﬁned by the DSM-V
criteria [1] including major depressive disorder (MDD),
anxiety and adjustment disorders, and persistent depres-
sive disorder in patients without somatic illnesses [2]. A
recent meta-analysis showed that antidepressants (ADs)
also reduce the number of depressive symptoms in physi-
cally ill populations [3] and in palliative care patients [4].
Furthermore, a review concluded that pharmacologic in-
terventions are effective in treating depressive disorders
in cancer patients [5]. Both the National Institute of
Clinical Excellence clinical guidelines on treatment and
management of depression in medically ill populations [6]
and the European guidelines on depression in palliative
care patients [7] recommend the use of ADs when a
depressive disorder has been diagnosed.
Depression is common among cancer patients, with a
pooled point prevalence rate of about 25% for all depres-
sive disorders and 15% for MDD [8]. Because the term
depression is often also used for depressive symptoms
and is assessed as such [9], the prevalence rates of depres-
sion in patients with advanced cancer vary considerably
across studies. Nevertheless, far from all patients with an
established depression diagnosis, receive recommended
treatment with ADs [10–13]. A study by Sharpe et al.
[10] of 5613 cancer outpatients who had no active cancer
disease showed that 8% met the screening criteria for
MDD, but only 15% of these were taking ADs. A study
conducted by Tiernan et al. [11] in 142 terminally ill
cancer patients referred for care at home or to admission
Copyright © 2014 John Wiley & Sons, Ltd.
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at a hospice inpatient unit showed that 18% had probable
depression (screened using the Hospital Anxiety and
Depression Scale) [14] and only 32% of these were
treated with ADs. A recent longitudinal study by Lloyd-
Williams [13] in 629 advanced cancer patients showed
that 32% scored 10 or above on the Patient Health Ques-
tionnaire 9 (PHQ-9) [15] and only one third of them
received AD medication.
This likely under-treatment with ADs highlights impor-
tant issues related to symptom management in patients
with advanced cancer. One is related to healthcare
providers’ increased awareness of depression and another
to the importance of recognizing risk factors for depres-
sion in somatically ill people. Variables associated with
depressive disorders in cancer patients have been rather
extensively researched, and patient characteristics such
as younger age [16], female gender [17], certain diagnoses
such as breast [18] and pancreatic cancer [19] and stage of
cancer disease [20] are found to be associated with depres-
sion. Still we lack data on characteristics of those cancer
patients with advanced disease that are treated with ADs.
A recent registry-based nationwide study demonstrated
that 22% (N= 3836) of Norwegian cancer patients who
died from cancer over a 2-year period had at least one
prescription of ADs in their last year of life, compared
with 6% in the general population [21]. Lower education,
lower income, and younger age were associated with the
use of ADs in that study, but the study design did not
allow an examination of clinical characteristics other than
cancer diagnosis.
The present report explores the use of ADs in a large in-
ternational multicentre sample including more than 1000
patients with advanced cancer, conducted by the European
Palliative Care Research Collaborative (EPCRC) (www.
epcrc.org). The research questions were as follows:
1. What was the prevalence of antidepressant medication
use in patients with advanced cancer?
2. Which sociodemographic and medical variables were
associated with the use of antidepressants?
Methods
Patients
The EPCRC computer-based symptom assessment study
[22] was a cross-sectional study involving 17 centres in
eight different countries that used the following four native
languages: Norwegian, Italian, English and German.
Patients were included from October 2008 to December
2009. Patients ≥18 years with incurable cancer, including
those receiving life-prolonging treatment, metastatic and/
or advanced loco-regional disease were eligible. According
to ethical regulations, it was not allowed to register any data
on those who were regarded as ineligible [22].
Data collection
The data collection was carried out using touch-sensitive
computers and consisted of two parts conducted on the
same day, one to be completed by healthcare professionals
and one by the patients [22]. The healthcare professionals
recorded the following: patient characteristics (e.g. age,
gender, marital status and living situation), sociodemo-
graphic data (e.g. education), disease characteristics
(primary cancer diagnosis, stage of disease, and co-
morbidities), Mini-Mental State Examination [23] for cog-
nitive function, Karnofsky Performance Status (KPS) [24],
current medication for pain, provision of care (hospital,
nursing home and home care), patient setting (inpatient
versus outpatient) and country. Length of survival was
calculated for each patient from date of inclusion to date
of death, with the date of censoring being January 2011.
Three survival categories were used: 1–90 days, 91–
270 days and 271 or more days (+271 days). Patients still
alive in January 2011 were coded as +271 days. A speciﬁc
question on the use of ADs, speciﬁed as ‘not as adjuvant
for pain’ required a dichotomous answer (no/yes) that
was registered by healthcare professionals.
The patient part consisted of self-report questionnaires
on symptoms and functioning [22]. PHQ-9 [15] was used
for self-report of depression, a commonly used instrument
for screening and diagnosing depression in medically ill
and palliative care populations. PHQ-9 includes nine
symptoms of depression, which correspond item by item
to the DSM-IV diagnostic criteria [25]. A diagnosis of
MDD is likely if ﬁve out of nine depressive symptom
criteria have been present at least ‘more than half of the
day’ in the last 2 weeks, where one of the symptoms has
to be either depressed mood or anhedonia. One of the nine
symptom criteria ‘thoughts that you would be better off
dead or of hurt yourself in some way’ counts if present
at all, regardless of how often it is experienced. Also,
depression can be categorized into no, minimal, mild,
moderate, moderately severe and severe according to an
established threshold [26] by summarizing the individual
patient scores on each item as seen in Table 1. Explana-
tory variables from the dataset to be used in the present
analyses were selected on the basis of empirical data
[21,27] and clinical guidelines [6,7].
Ethical considerations
The study was performed according to the Declaration of
Helsinki. Approval from ethical committees and other reg-
ulatory bodies were obtained as necessary in each country.
Written informed consent was obtained from all patients.
Statistical analysis
Standard descriptive statistics were used. The prevalence
of AD use and its 95% conﬁdence interval (95% CI) were
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calculated. Univariate and multivariate logistic regression
models were applied to study variables potentially associ-
ated with the use of ADs, which was the dependent
variable. The following potentially independent variables
were tested in univariate models: gender, age, living
situation, education, primary cancer diagnosis, inpatient
or outpatient, stage of disease, current pain medication,
KPS score, number of co-morbidities and length of
survival as a proxy variable for prognosis of the disease
at assessment time. Continuous variables (age, KPS and
number of co-morbidities) were categorized. The set of
variables showing statistically signiﬁcant (p< 0.05) asso-
ciations with the use of ADs in the univariate analysis
was tested using backward elimination in a multivariate
logistic regression model. It was adjusted by country to
account for a potential lack of independency among obser-
vations from the same country. The regression model was
not adjusted by the level of depression as measured by
PHQ-9 because of the potential inﬂuence by the depen-
dent variable (use of ADs). Nagelkerke pseudo-R2 and
area under the receiver operating characteristic curve
(C statistics) [28] were used to examine the overall perfor-
mance and discrimination capability of the ﬁnal model;
according to Hosmer and Lemeshow [29], the model is
considered to have outstanding discrimination when
C≥ 0.9, the model has excellent discrimination if 0.8≤
C< 0.9, the discrimination is acceptable if 0.7≤C< 0.8
and the model has no discriminative capability (discrimi-
nant capability of an empty model) if C = 0.5. Results
are presented in terms of odds ratios with corresponding
Table 1. Patient characteristics (n= 1048)
Variable (missing) Frequency (% rounded) Mean (SD)
Gender
Male 540 (52)
Female 508 (48)
Age (years) 62.5(12.3)
18–50 169 (16)
51–70 610 (58)
71+ 269 (26)
Marital status
No spouse 360 (34)
Spouse 688 (66)
Living situation
Not alone 773 (74)
Alone 275 (26)
Education (2) (years)
<10 367 (35)
10–12 370 (35)
>12 309 (29)
Primary cancer diagnosis (1)
Digestive organs 274 (26)
Respiratory organs 177 (17)
Breast cancer 177 (17)
Male genital organs 113 (11)
Other 306 (29)
Patient setting
Inpatient 597 (57)
Outpatient 451 (43)
Provision of care
Hospital 952 (91)
Nursing home 17 (2)
Home care 79 (7)
Stage of disease/current medical status
Loco-regionally advanced 161 (15)
Metastatic 887 (85)
Receiving antidepressants
No 907 (86)
Yes 141 (14)
Current medication for pain
No 364 (35)
Yes 684 (65)
MMSE (28) 28 (2.94)
KPS scoresb (10) 70 (16.9)
0–40 96 (9)
50–70 506 (48)
80–100 436 (42)
Co-morbiditya
Heart 244 (23)
Arthritis 71 (7)
COPD 81 (8)
Renal 47 (5)
Liver 36 (3)
Other 301 (29)
Country
Norway 520 (50)
Austria 100 (9)
Italy 102 (10)
Switzerland 98 (9)
England 85 (8)
Australia 70 (7)
Canada 34 (3)
Germany 39 (4)
Continues
Table 1. Continued
Variable (missing) Frequency (% rounded) Mean (SD)
Major depressive disorderc (81)
Depression not present 835 (80)
Depression present 132 (12)
Depression severityd (81)
0–4 291 (28)
5–9 370 (35)
10–14 196 (19)
15–19 79 (7)
20–27 31 (3)
Survival (94) (days)
1–90 272 (26%)
91–270 262 (25%)
271+ 420 (40%)
SD, standard deviation; MMSE, Mini-Mental State Examination; KPS, Karnofsky Perfor-
mance Status; COPD, chronic obstructive pulmonary disease.
aPatients may have more than one co-morbidity.
bKPS scores: 100–80 = no care needed; 70–50 = unable to work, assistance needed;
40–0 = unable to care, dead.
cPatients with depression are identiﬁed by DSM-IV-based scoring algorithm in Patient
Health Questionnaire 9 (PHQ-9). Diagnosis of major depressive disorder is calculated
when ﬁve of the nine symptoms are endorsed, including at least depressed mood and
anhedonia.
dDepression severity was measured by dividing the PHQ-9 scores into the following
categories: 0–4 =minimal, 5–9 =mild, 10–14 =moderate, 15–19 =moderately severe
and 20–27 = severe.
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95% CIs for both univariate and multivariate analyses. All
the statistical analyses were performed using STATA 12.0
software (STATA Corp., College Station, TX, USA).
Results
Demographic and clinical characteristics of the 1048
advanced cancer patients with data on the use of ADs
are summarized in Table 1. The gender distribution was
relatively similar (male 52% versus female 48%), and
most patients were above 50 years of age (mean 62, range
18–91). At the time of participation, 887 patients (85%)
had metastatic disease, and 597 patients (57%) were re-
ceiving inpatient care. Forty per cent of the patients lived
9 months or longer after the assessment. Overall, 141
(14%, 95% CI 11–16%) patients received ADs other than
as adjuvant for pain. Of these 141 patients, 25% fulﬁlled
the criteria for MDD measured by PHQ-9 at the time of
data collection, whereas 75% who used ADs did not fulﬁl
the criteria for an MDD at the time of assessment.
Table 2 provides the percentage on the use of ADs
according to sociodemographic and clinical variables and
the corresponding odds ratios with 95% CIs estimated by
univariate logistic regression models. Results showed sig-
niﬁcantly higher odds for AD use among women, younger
patients (<50 years), those taking painmedication and those
with lower performance status and multiple co-morbidities.
Multivariate regression analysis (Table 3) conﬁrmed the
signiﬁcance of the associations found in the univariate analy-
sis for all factors but KPS. Thus, younger age, female gender,
current medication for pain and the presence of three or more
co-morbidities were associated with the use of ADs.
Nagelkerke pseudo-R2 of 11.8% indicates a limited capabil-
ity of the model to explain observed variability in AD use.
The C statistics was 0.70. This indicates that the model had
a low discriminating capability [29] between patients taking
and not taking ADs, if we consider that the empty model,
containing only the adjustment variable (country), had a C
statistics of 0.59, which should be considered the reference
value. In order to test for sensitivity to variable categoriza-
tion, the model selection was replicated using continuous
variables for age, KPS and number of co-morbidities, which
led to substantially unmodiﬁed results (data not shown).
Discussion
In this large international cross-sectional multicentre study
in advanced cancer patients, the prevalence of AD use was
14%. Several factors were associated with the use of ADs:
younger age, female gender, current pain medication and
multiple co-morbidities.
The interpretation of the results should be treated with
some caution because of the cross-sectional, descriptive
study design and the convenience sample. A more detailed
registration of the use of ADs including indication would
have given important information about treatment out-
comes. Furthermore, the study design provides no infor-
mation about the initiation and length of AD use;
however, this was beyond the scope of this cross-sectional
study. The fact that 75% of the patients using ADs did not
fulﬁl the criteria for MDD may partially be caused by a
positive effect of the medication. Also, statistical analyses
on the characteristics of patients with or without MDD
who received ADs were prohibited by small subgroups.
Table 2. Odds ratio (and 95 % CI) from binary logistic regression
showing association with the use of antidepressants
Use of antidepressants in the sample of 1048 patients
Yes No
OR (95 % CI)N=141 N= 907
Gender
Male 59 (10.9) 481 (89.1) 1
Female 82 (16.1) 426 (83.9) 1.56 (1.09–2.24)
Age (years)
18–50 31 (18.3) 138 (81.7) 2.19 (1.24–3.86)
51–70 85 (13.9) 525 (86.1) 1.58 (0.98–2.53)
71+ 25 (9.3) 244 (90.7) 1
Living situation
Not alone 103 (13.3) 670 (86.7) 1
Alone 38 (13.8) 237 (86.2) 1.04 (0.69–1.55)
Education (years)
<10 50 (13.6) 317 (86.4) 1
10–12 53 (14.3) 317 (85.7) 1.06 (0.70–1.61)
>12 38 (12.3) 271 (87.7) 0.89 (0.56–1.40)
Primary cancer diagnoses
Digestive organs 41 (15.0) 233 (85.0) 1
Respiratory organs 23 (13.0) 154 (87.0) 0.84 (0.49–1.47)
Breast 27 (15.3) 150 (84.7) 1.02 (0.60–1.73)
Male genital organs 9 (7.9) 104 (92.0) 0.85 (0.53–1.37)
Other 49 (11.7) 370 (88.3) 0.85 (0.53–1.37)
Patient setting
Inpatient 78 (13.1) 519 (86.9) 1
Outpatient 63 (14.0) 388 (86.0) 1.08 (0.75–1.54)
Stage of disease/current
medical status
Loco-regionally advanced 26 (16.1) 135 (83.9) 1
Metastatic 115 (13.0) 772 (87.0) 0.77 (0.48–1.22)
Current medication for pain
No 24 (6.6) 340 (93.4) 1
Yes 117 (17.1) 567 (82.9) 2.92 (1.84–4.62)
KPS scoresa
0–40 18 (18.8) 78 (81.2) 1.91 (1.05–3.46)
50–70 75 (14.8) 431 (85.2) 1.44 (0.97–2.12)
80–100 47 (10.8) 389 (89.2) 1
Number of co-morbidities
0 56 (11.0) 453 (89.0) 1
1–2 69 (14.0) 425 (86.0) 1.31 (0.90–1.91)
3 or more 16 (35.6) 29 (64.4) 4.46 (2.28–8.72)
Survival (days)
1–90 41 (15.1) 231 (84.9) 1
91–270 38 (14.5) 224 (85.5) 0.95 (0.59–1.54)
271+ 54 (12.9) 366 (87.1) 0.83 (0.54–1.29)
Bold values represent odds ratios and 95%CIs showing statistically signiﬁcant difference (ORs
differ signiﬁcantly from 1) between the categories of patients taking and not taking ADs.
KPS, Karnofsky Performance Status; OR, odds ratio; CI, conﬁdence interval.
aKPS scores: 100–80 = no care needed; 70–50 = unable to work, assistance needed;
40–0 = unable to care, dead.
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As we were not allowed to register data on nonpartici-
pants, speciﬁc subgroup analyses were not performed. In
general, the study population was relatively young as
compared with those of other studies in advanced cancer
patients, as the mean age was 62.5 years with the majority
of the patients being 70 years or younger. One explanation
for this may be that there was a presupposition among the
staff thinking that older people are not interested in taking
part in a computerized assessment or that older patients
were not approached.
Our study has, however, several strengths: ﬁrst and fore-
most, related to the overall sample size, where according to
the primary aim of the study, investigating the assessment
of symptoms by a computer in advanced cancer patients
was a feasible method and gives a good overview of the
prevalence of depression. In addition, the assessment tool
for depression was based on the DSM criteria, whereas
many of the studies on prescription prevalence
[21,27,30,31] did not include diagnostic information when
presenting the prevalence rates. Furthermore, the study
represents interesting data on AD use from a large interna-
tional sample from eight different countries.
A prevalence of 14% of AD use is consistent with the
ﬁnding by Ashbury et al. [27] showing that 16% of the
included community cancer patients were receiving ADs.
A recent Spanish study [30] in patients with advanced
cancer reported a signiﬁcant increase in the prescription
of psychotropic drugs from 18% to 27% in the period
2002 to 2009. A registry-based nationwide study
conducted by Brelin et al. [21] showed the one year point
prevalence of ADs prescribed to be 22% in Norwegian
cancer patients during their last year of life. This study is
in line with other studies also showing that ADs are often
prescribed close to death and in fact so late that the thera-
peutic effect may be questionable [31,32]. In the present
study, healthcare providers were directly asked whether
the indication for using ADs was other than as adjuvant
pain medication in contrary to other studies, in which this
cannot be ascertained [27,30,33]. For example, in the
registry-based study by Brelin et al. [21], the authors
made an assumption regarding the dosage of tricyclic
ADs (TCA), related to the Norwegian prescription recom-
mendations. They regarded TCA doses below 50 mg per
day as an indication of pain treatment, which only applied
to a small proportion of the total prescriptions of ADs in
this rather large study (n> 17,000 people). In addition,
none of these studies [21,27,30,31] recorded the diagnosis
of depressive disorder but only reported the prevalence
rates of AD prescription.
The prevalence of AD use in the present study was
higher in women than in men, as shown in the general
population [34] and cancer population [31]. However, re-
sults regarding the association of gender with depression
differ in the literature. Older age has been shown as a sig-
niﬁcant predictor of AD prescription in the general popu-
lation [35]; however, in the present study, we found that
AD use was more common in younger patients, as shown
elsewhere [21]. This might be explained by the acceptance
of depressive symptoms by healthcare providers as a
normal part of the ageing process. On the other hand, there
might be an increasing awareness that younger patients
with metastatic cancer are at a higher risk of developing
depression than the older age group [16] when those
patients are facing life-threatening disease at an early stage
of their lives. Level of education has invariably been
shown to be associated with the use of ADs, with higher
levels leading to less use of ADs [21]. However, in our
study, no such relation has been reported, in line with
other study [36]. Patients with lung cancer may be at a
greater risk of developing depressive disorder compared
with patients having cancer of other organs [18] or having
more advanced stage of cancer disease [20]. The present
study, however, was conducted in patients with different
cancer diagnosis, showing no association between cancer
type and use of ADs, nor with stage of disease and use
of ADs, as reported in other studies on depression [37,38].
Patients receiving pain medication were 2.6 times more
likely to be using ADs, compared with those who did not.
Pain is one of the most prevalent and feared symptoms
among cancer patients in general, inﬂuencing patients’
quality of life [39]. Pain and depression have been shown
to be interdependent; however, the causality of this rela-
tionship is still unclear [40]. Our study design did not
permit further exploration of this. In addition, patients
with three or more chronic co-morbid conditions were
four times more likely to receive ADs compared with
patient without co-morbidity. This may in part be
explained by higher levels of depression or depressive
symptoms in patients with chronic co-morbid conditions
and in patients experiencing higher disease burden, as
reported elsewhere [41]. Our ﬁndings in this respect
conﬁrm results from a study showing a higher likelihood
Table 3. Multivariate logistic regression of variables associated
with the use of antidepressants (n= 1048)
Variables OR (95% CI)
Gender
Male 1
Female 1.59 (1.09–2.33)
Age (years)
18–50 2.46 (1.32–4.55)
51–70 1.81 (1.10–2.97)
71+ 1
Current medication for pain
No 1
Yes 2.68 (1.65–4.33)
Number of co-morbidities
0 1
1–2 1.46 (0.97–2.17)
3 or more 4.74 (2.27–9.91)
OR, odds ratio; CI, conﬁdence interval.
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of AD use among community cancer patients with co-
morbidities and on pain medication [27].
Low physical performance as measured by KPS gave
higher odds for receiving ADs in the binary logistic regres-
sion, while it was not statistically signiﬁcant in the multivar-
iate model. The fact that co-morbidity was retained in the
multivariate model probably shares variance with KPS as
depression disorder is accompanied by poor performance
status and use of ADs might (therefore) have improved
performance status.
Conclusions
In conclusion, this cross-sectional study of a convenience
sample of advanced cancer patients showed that the prev-
alence of AD use was relatively low (14%) and that the
use was associated with certain sociodemographic and
disease characteristics (female gender, younger age, med-
ication for pain and multiple co-morbidities). The fact that
only 25% of the patients receiving ADs fulﬁlled the
criteria for an MDD at the time of patient assessment
may indicate that the medication had been effective. The
variables associated with the use of ADs in the present
study are partially different from the variables shown to
be associated with depression in advanced cancer patients.
However, information is still limited on which variables
are guiding physicians to prescribe AD medication. There
is a need to further explore how to better identify patients
in need of treatment in order to improve clinical practice.
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9. APPENDIX 
Contents 
1. Search strategies in four bibliographic databases (paper I) 
2. EAPC basic dataset 
3. Karnofsky Performance Status scale (paper II) 
4. Patient Health Questionnaire - 9 (paper II) 
5. Survey questionnaire (paper III) 
6. Flow diagram of patient selection process (paper III) 
  
Search strategies in four bibliographic databases (Paper I) 
Search strategy for PubMed (througth NCBI/NIH) 
Search Query Items found 
#1 Search Depressive disorder[mh] OR Depression[mh] OR depression[tiab] 
OR depressive[tiab] 
246253 
#2 Search Palliative care[mh] OR palliat* [tiab] OR Terminal care[mh] OR 
terminal care[tiab] OR end-of-life care[tiab] OR supportive care[tiab] OR 
comfort care[tiab] OR Hospices[mh] OR hospice*[tiab] OR Terminally 
ill[mh] 
97828 
#3 Search terminal*[tiab] AND (ill[tiab] OR illness*[tiab]) 6500 
#4 Search advanced[tiab] AND cancer[tiab] 69615 
#5 Search #2 OR #3 OR #4 163192 
#6 Search #1 AND #5 2568 
#7 Search #6 AND cancer[sb] 1593 
#8 Search 7 Limits: Publication Date from 2007 635 
 
Search strategies for CINALH (through EBSCO host edition 1982 to December 2011) 
MH “Palliative Care” OR TI palliat* OR AB palliat* OR MH "Terminal Care" OR TI "terminal care" 
OR AB "terminal care" OR MH "Hospice and Palliative Nursing" OR MH "Hospices" OR MH 
"Hospice Care" OR MH "Terminally ill patients+ " OR TI hospice* OR AB hospice* OR TI "end of 
life care" OR AB "end of life care" OR TI "comfort care" OR AB "comfort care" OR TI "supportive 
care" OR AB "supportive care" OR TI (advanced N5 cancer) OR AB(advanced N5 cancer) OR TI 
"terminal* ill*" OR AB "terminal* ill*" 
AND 
MH Depression OR TI depression OR AB depression OR TI depressive OR AB depressive 
AND 
MH Neoplasms + OR TI cancer* OR AB cancer* OR TI tumor* OR AB tumor* OR TI tumour* OR 
AB tumour* OR TI malignan* OR AB malignan* OR TI oncolog* OR AB oncolog* OR TI neoplas* 
OR AB neoplasm* OR TI carcinoma* OR AB carcinoma* OR TI leukem* OR AB leukem* 
AND 
‘Refine your results’ > Abstract available 
‘Source type’ > Academic journals 
‘Refine your results’ > Published Date from: 20070101-20111231 
 
 Search strategy for PsycINFO (through OvidSP, edition 2002 to December Week 4 2011) 
1 Palliative care/ OR palliat*.ti,ab. OR terminal care.ti,ab. OR Exp 
hospice/ or hospice*.ti,ab. OR end of life care.ti,ab. OR comfort 
care.ti,ab. OR supportive care.ti,ab. OR Terminally ill patients/  OR 
Terminal cancer/ OR terminal* ill*.ti,ab. OR (advanced adj5 
cancer).ti,ab. 
8311 Advanced 
2 "Depression (emotion)"/ OR Major depression/ OR depression.ti,ab. 
OR depressive.ti,ab. 
84658 Advanced 
3 Exp Neoplasms/ OR Oncology/ OR cancer*.ti,ab. OR tumor*.ti,ab. OR 
tumour*.ti,ab. OR malignan*.ti,ab. OR oncolog*.ti,ab. OR 
neoplas*.ti,ab. OR carcinoma*.ti,ab. OR leukem*.ti,ab. 
27705 Advanced 
4 1 and 2 and 3 345 Advanced 
5 Limit 4 to yr=”2007 – Current” 220 Advanced 
6 5 and (journal or peer reviewed journal).pt. 204 Advanced 
 
Search strategy for Embase (through OvidSP edition 1996 to 2011 Week 52) 
1 exp Palliative therapy/ OR Palliative nursing/ OR palliat*.ti,ab. OR 
Hospice/ OR Hospice nursing/ OR exp Terminal care/ OR terminal 
care.ti,ab. OR “end of life care”.ti,ab. OR comfort care.ti,ab. OR 
supportive care.ti,ab. OR hospice*.ti,ab. OR Advanced cancer/ OR 
(advanced adj5 cancer).ti,ab. OR exp Terminally ill patient/ OR 
Terminal disease/ OR terminal* ill*.ti,ab. 
135791 Advanced 
2 exp Depression/ OR depression.ti,ab. OR depressive.ti,ab. 245932 Advanced 
3 Exp Neoplasm/ OR cancer*.mp. OR tumor*.mp. OR tumour*.mp. OR 
malignan*.mp. OR oncolog*.mp. OR neoplas*.mp. OR 
carcinoma*.mp. OR leukem*.mp. 
2049486 Advanced 
4 1 and 2 and 3 2467 Advanced 
5 4 not (review. pt. or Case study/) 1897 Advanced 
6 Limit 5 to (abstracts and human and embase) 1120 Advanced 
7 Limit 6 to yr – “2007 – Current” 605 Advanced 
8 7 and (‘2007’.yr. or “200800”.em. or “200900”.em. or 2010”.em. or 
2011”.em.) 
603 Advanced 
9 7 not 8 2 Advanced 
 
  
 BASIC DATASET 
PATIENT FORM 
 What is your: Please fill in or tick the right box as appropriate. 
1 
 
Date of birth  
(Day. Month. Year) 
2 Gender පMale 
පFemale 
3 Living 
situation 
පAlone 
පWith spouse/partner 
පWith spouse/partner or child 
පWith children 
පWith other adult(s) 
පIn an institution 
පOther 
4 Highest 
completed 
level of 
education 
පPrimary school 
පSecondary school/high school 
පCollege/university 
5 Ethnicity  
 Symptoms. Please circle the number that best describes how you feel NOW: 
6 No Pain 0    1    2    3    4    5    6    7    8    9    10 Worst Possible 
Pain 
7 No Tiredness 
(tiredness=lack of 
energy) 
0    1    2    3    4    5    6    7    8    9    10 Worst Possible 
Tiredness 
8 No Drowsiness 
(Drowsiness=feeling 
sleepy) 
0    1    2    3    4    5    6    7    8    9    10 Worst Possible 
Drowsiness 
9 No Nausea 0    1    2    3    4    5    6    7    8    9    10 Worst Possible 
Nausea 
10 No Lack of Appetite 0    1    2    3    4    5    6    7    8    9    10 Worst Possible 
Lack of Appetite 
11 No Shortness of 
Breath 
0    1    2    3    4    5    6    7    8    9    10 Worst Shortness of 
Breath 
12 No Depression 
(Depression=feeling 
sad) 
0    1    2    3    4    5    6    7    8    9    10 Worst Possible 
Depression 
13 No Anxiety 
(Anxiety=feeling 
0    1    2    3    4    5    6    7    8    9    10 Worst possible 
Anxiety 
nervous) 
14 Best Wellbeing 
(Wellbeing=how you 
feel overall) 
0    1    2    3    4    5    6    7    8    9    10 Worst Possible 
Wellbeing 
15 Best Sleep 0    1    2    3    4    5    6    7    8    9    10 Worst Possible 
Wellbeing 
16 No Constipation 0    1    2    3    4    5    6    7    8    9    10 Worst Possible 
Constipation 
17 No Vomiting 0    1    2    3    4    5    6    7    8    9    10 Worst Possible 
Vomiting 
 
 BASIC DATASET 
HEALTH CARE PERSONELL FORM 
 Patient’s: Please fill in or tick the right box as appropriate 
18 
 
Date of birth  
(Day. Month. Year) 
19 Principal 
diagnosis 
ICD-10 code: 
20 Date of the 
principal 
diagnosis 
 
(Month. Year) 
21 Stage of the 
cancer disease 
පLocal 
පLocally advanced 
පMetastatic/disseminated 
22 Site of 
metastases 
පBone 
පLiver 
පLung 
පCNS 
පOther 
23 Present 
anticancer 
treatment 
පRadiotherapy 
පChemotherapy 
පHormone therapy 
පOther anticancer therapy 
පNo anticancer therapy 
24 Additional 
diagnoses 
ICD-10 code: __________, __________, __________, __________, 
__________, __________, __________. 
25 Stage of the 
non-cancer 
disease 
Chronic heart failure (CHF): New York Heart Association (NYHA) 
Functional Association; NYHA class: I ප, II ප, III ප, IV ප 
Chronic Obstructive Pulmonary Disease (COPD): GOLD classification; 
Stage: I ප, II ප, III ප, IV ප 
Dementia: FAST scales; stage 1 ප, 2 ප, 3 ප, 4 ප, 5 ප, 6 ප, 7 ප 
26 Medication පNon-opioid analgesics 
පOpioids 
පCo-analgesics 
පCorticosteroids 
පAntidepressants 
පAntiemetics 
පNeuroleptics 
පSedatives/anxiolytics 
පDrug(s) for acid related disorders 
පLaxatives 
පAntibiotics 
පDiuretics 
පHeart medication/antihypertensives 
පOther 
27 Weight loss Involuntary weight loss ____% and duration of weight loss___months 
28 Performance 
status 
ප 100 Normal, no complaints; no evidence of disease. 
ප  90 Able to carry on normal activity; minor signs or symptoms. 
ප  80 Normal activity with effort; some signs or symptoms of disease. 
ප  70 Cares for self; unable to carry on normal activity or to do active 
work. 
ප  60 Requires occasional assistance and frequent medical care. 
ප  50 Requires considerable assistance and frequent medical care. 
ප  40 In bed more than 50% of the time. 
ප  30 Almost completely bedfast. 
ප  20 Ty bedfast and requiring extensive nursing care by professionals 
and/or family. 
ප  10 Comatose or barely arousable. 
ප   0 Dead 
29 Cognitive 
function 
The patient has cognitive impairment; 
පNo 
පMild 
පModerate 
පSevere 
30 Placed of care පHome 
පLon-term care facilities 
පHospice/palliative care unit 
පHospital 
පOther 
31 Provision of 
care 
පInpatient 
පOutpatient 
පDay care 
Karnofsky Performance Status (KPS) scale 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Per cent Criteria 
 
100% 
 
Normal; no complaints; no 
evidence of disease. 
90% Able to carry on normal 
activity; minor signs or 
symptoms of disease. 
80% Normal activity with 
effort; some signs or 
symptoms of disease. 
70% Cares for self. Unable to 
carry on normal activity or 
to do active work. 
60% Requires occasional 
assistance, but is able to 
care for most of his needs. 
50% Requires considerable 
assistance and frequent 
medical care. 
40% Disabled; requires special 
care and assistance. 
30% Severely disabled; 
hospitalization is indicated 
although death not 
imminent. 
20% Very sick; hospitalization 
necessary; active 
supportive treatment 
necessary. 
10% Moribund; fatal processes 
progressing rapidly. 
0% Dead. 



  
 
 
 
 
 
 
Survey questionnaire used in paper III 
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 General 
1.In respect of this death, where you acting as: ප specialist/specialist-in-training/assistant-specialist-not-in-training 
ප general practitioner/general-practitioner-in-training 
පnursing-home physician/nursing-home-physician-in-training 
පa different function to those named above 
2. When was your first contact with the patient? පbefore or at the time of deathї go to question 3 
පafter deathї go to question 25 
3. Did death occur suddenly and totally unexpectedly?පyesї go to question 24 
පnoї go to question 4 
 
Medical practices 
4.Did you or another physician carry out one or more of the following acts (or ensure that one of them was carried out), 
taking into account the probability or certainty that this act would hasten the end of the patient's life: 
(please answer 4a, 4b and 4c) 
4a. withholding a treatment*? පyes 
පno 
If yes, which treatments were withheld?  
4b. withdrawing a treatment*? පyes 
පno 
If yes, which treatments were withdrawn?  
4c. intensifying the alleviation of pain and/or 
symptoms by using a drug? 
පyes 
පnoї go to question 6 
If yes, which drugs were used? 
(please tick as many answers as apply) 
පmorphine or morphine-derivative 
පbenzodiazepine 
පother drug 
5. Was hastening the end of life partly the 
intention of the act indicated in question 4c? 
පyes 
පno 
6.Was death the consequence of one or more of the following acts, which you or another physician decided to carry out 
with the explicit intention of hastening the end of life*: 
(please answer both 6a and 6b) 
6a. Withholding a treatment**? පyes 
පno 
If yes, which treatments were withheld?  
6b. Withdrawing a treatment**? පyes 
පno 
If yes, which treatments were withdrawn?  
7.Was death the consequence of the use of a drug 
that was prescribed, supplied or administered by 
you or another physician with the explicit 
intension of hastening the end of life (or of 
enabling the patient to end his or her own life)? 
පyes 
පno 
If yes, who administered this drug (=introduce 
edit in to the body)? 
(please tick as many answers as apply) 
 
පthe patient 
පyou or another physician 
පnursing staff 
පsomeone else 
If yes, which drugs were used? 
(please tick as many answers as apply) 
 
පneuromuscular relaxant 
පbarbiturate 
පbenzodiazepine 
පmorphine or a morphine derivative 
පbenzodiazepine 
පother drug 
*In this study, 'treatment' includes artificial feeding and/or 
hydration. 
**Either 'hastening the end of life' or 'not prolonging life'. 
 Decision making about last- mentioned act 
Other issues concerning the last-mentioned act 
Note: If all parts of questions 4, 5, 6 and 7 were answered with 'no', go to question 20. Questions 8 through 19 
relate to the last-mentioned act, that is, the last 'yes' in answer to questions 4 to 7. 
8. A question about that last-mentioned 
act: In your estimation, how much was 
the patient's life shortened by this act? 
පmore than six months 
පone to six months පone to 
four weeks පup to one 
week පless than 24 hours 
lif b bl9. Did you or another physician discuss 
with the patient the (possible) 
hastening of the end of life as a result 
of the last-mentioned act? 
පyes, at the time of carrying out the act or shortly before 
පyes, sometime before hand 
පno, no discussionї go to question13 
10. At the time of the discussion, did you 
consider the patient able to assess his/her 
situation and to make a decision about it 
පyes 
පno ,not fully able 
පno, not able at all 
11. Was the decision concerning the last-
mentioned act made up on an explicit 
request of the patient? 
 
පyes upon an oral request 
පyes, upon a written request 
පyes upon both an oral and a written request 
පno ї go to question 16 
12. At the time of this request, did you 
consider the patient able to assess 
his/her situation and to make a decision 
පyesї go to question 16 
පno, not fully ableї go to question 16 
පno, not able at allї go to question 16 
13. Did you consider the patient able to 
assess his/her situation and to make a 
decision about it adequately? 
පyes 
පno, not fully able 
පno, not able at all 
14. Why was the (possible) hastening of the 
end of life as are sult of the last-mentioned 
act not discussed with the patient? 
(please tick as many answers as apply) 
 
පpatient was too young 
පthis last-mentioned act was clearly in the best interest of the 
patient 
පdiscussion would have done more harm than good 
පpatient was unconscious 
පpatient had dementia 
පpatient was mentally handicapped 
පpatient was suffering from a psychiatric disorder 
පother, please elaborate at the end of the questionnaire 
15. As far as you know, did the patient 
ever express a wish for the end of life to 
be hastened? 
පyes, explicitly 
පyes, but not explicitly 
පno 
16.Did you or another physician discuss the 
(possible) hastening of the end of life with 
others previous to making a decision about 
the last-mentioned act? 
(please tick as many answers as apply) 
පyes, with one or more other physicians 
පyes, with nursing staff 
පyes, with partner or relatives 
පyes, with someone else 
පno 
If the (possible) hastening of the end of 
life was discussed with one or more other 
physicians: did this discussion once rnan 
official consultation as required by the 
review procedure? (please tick as many 
answers as apply) 
 
පyes, consultation faSCEN-physician 
පyes, consultation of another physician 
පno 
 17. Which were the most important reasons to make the 
decision about the last-mentioned act? 
(please tick as many answers as apply) 
 
පpatient had (severe) pain 
පpatient had (severe) other symptoms 
පrequest or wish of the patient 
පrequest or wish of relatives 
පexpected suffering of the patient 
පno chance of improvement 
පno futile prolongation of life 
පother:................................................................................... 
 
18. What do you think would be the best label for the last-
mentioned act? 
 
පabandoning treatment 
පalleviation of symptoms 
පpalliative or terminal sedation 
පending of life 
පeuthanasia 
පassisted suicide 
පother:................................................................................ 
19. Did you or another physician report the last-mentioned 
act to a regional review committee e because of the review 
procedure for the ending of life upon the request of a 
patient? 
 
පyes 
පno, because 
පit was no ending of life 
පreporting gives to much hassle 
පending of life is the privacy of the patient and the physician 
පthe requirements for careful practice were possible not met 
පbecause of possible legal consequences 
පother:.......................................................................... 
 
Care and treatment 
20. To what extent, in your opinion, were the following 
signs or symptoms present in the patient during the 
last 24 hours before death (despite possible 
treatment)? 
 
                                                      1 2 3 4 5 
No painපපපපපsevere pain 
No vomitingපපපපපsevere vomiting 
No fatigueපපපපපsevere fatigue 
No dyspnoeaපපපපපsevere dyspnoea 
Not confusedපපපපපvery confused 
Not depressedපපපපපvery depressed 
Not anxiousපපපපපvery anxious 
Consciousපපපපපunconscious 
21. Which caregivers were involved in the care for the 
patient during the last month before death (beside 
yourself and as far as you know)? 
(please tick as many answers as apply) 
 
පgeneral practitioner 
පmedical specialist 
පspecialist in alleviation of pain 
පnursing home physician 
පpalliative consultant or palliative team 
පpsychiatrist or psychologist 
පnursing staff 
පspiritual caregiver 
පvolunteer 
22. Was the patient continuously and deeply 
sedated or kept in coma before death? 
පyes 
පnoї go to question 23 
Which medication was given for 
sedation? (please tick as many 
answers as apply) 
 
පmidazolam 
පother benzodiazepine 
පmorphine or a morphine derivative 
පother type of medication 
At what time before death was continuous sedation of 
the patient started? 
 
ප……hours before death  
ප……days before death 
ප……weeks before death 
Did the patient receive artificial nutrition or 
hydration during sedation? 
පyes 
පno 
  
Finally 
25.Pleaseprovideanycommentstoanswerstothepreviousquestionsyouwishtoclarifyorexpand:..............................................................
....................................................................................................................................... 
..................................................................................................................................... ........................................................................ 
.......................................................................................................................................... ................................................................... 
……………………………………………………………………………………………………………………………………………………………………………………………………  
……………………………………………………………………………………………………………………………………………………………………………………………………  
 
End of the questionnaire  
23. Did the patient receive morphine or a morphine 
derivative during the last 24 hours before death? 
පyes 
පnoїgotoquestion24 
 
 
Name and dos age of the 
medication? (please tick as many 
answers as apply) 
 
 
Type of medication 
Totalamountduringthel
ast24 hours before 
death 
Plasters ප phentanyl …….. ђg/hr 
Pump  ප morphine …….. mg 
Injecton 
 
පmorpine 
පpiritramide 
……mg 
…….. ml 
Suppository පmorphine …….. mg 
Drink 
 
පmorphine 
පmethadone 
…….. ml 
…….. ml 
Tablets 
 
ප morphine retard (eg  
    MSContin®) 
පmorphine (eg Sevredol®)  
පtramadol (eg Tramal®) 
පoxicodon (eg Oxycontin®) 
…….. mg 
 
…….. mg 
…….. mg 
…….. mg 
Droplets පtramadol (egTramal®) …….. 
Other පmedication:…………………… 
පway of administration:…………
........ mg 
Was a higher dose than necessary given to alleviate pain or 
other symptoms? 
ප yes 
ප no 
How much time before death was the administration of 
morphine or a morphine derivatives tarted? 
ප……hours before death 
ප……days before death 
ප……weeks before death 
Which figure best illustrates the dosage of morphine 
or a morphine derivative doses during the last 3 days 
before the patient’s death? 
ප No increase පGradual increase පStrong increase last day 
 
  
24. Did the patient make an explicit request to end his 
or her life which was not granted? 
ප yes 
ප noї go to question 25 
Why was this request not granted? 
(please tick as many answers as 
apply) 
 
ප patient died before it could be granted 
ප suffering was not unbearable 
ප suffering was not hopeless 
ප there was no well-considered request of the patient 
ප there was no voluntary request of the patient 
ප due to the institutes’ policy 
ප due to fundamental objections against end of life 
ප patient withdrew the request 
ප other, please elaborate at the end of the questionnaire 
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9965cases in the dataset 
First contact after death (n=848)** 
Sudden or unexpected death (n=635)*** 
5342questionnaires returned 
No questionnaire sent (Strata 1, instant 
death*) (n=3105) 
3859 
Non-cancer patients (n=1508): 
-Heart disease (n=661) 
-Respiratory system disease (n=213) 
-Nervous system disease (n=101) 
-Other/unknown (n=533) 
3738 
Unconscious patients with scores of 4 and 5 
(n=709) 
1521 
Patients <17 years old (n=121) 
2230 
6860questionnaires mailed 
No questionnaire returned (n=1518). Response 
rate 77,8% 
Missing data on outcome (n=158) 
1363 
 *Strata 1: Patients with instant death (e.g. car accident) were assigned to Stratum 1. Cases 
from stratum 1 did not receive any assistance from physician, consequently questionnaires 
were not sent. 
**If attending physician had the first contact to the patient after patients’ death the 
questionnaire was returned back (from question 2 move to question 25).  
***If death of the patient occur suddenly and totally unexpectedly for attending physicians  
(from question 3 move to question 24). 
 
 
